Paclitaxel solution
Based on 422 publication(s) in Google Scholar
Paclitaxel solution is mainly composed of Paclitaxel (HY-B0015). Paclitaxel is a naturally occurring antineoplastic agent and stabilizes tubulin polymerization. Paclitaxel can cause both mitotic arrest and apoptotic cell death. Paclitaxel also induces autophagy.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 33069-62-4
- Formel: C47H51NO14
- Molecular Weight:853.91
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Paclitaxel solution
More- Signal Transduct Target Ther. 2025 Dec 15;10(1):406. [Abstract]
- Signal Transduct Target Ther. 2022 Sep 12;7(1):317. [Abstract]
- Nature. 2026 Oct;658(8137):1066-1076. [Abstract]
- Nat Med. 2024 Mar;30(3):749-761. [Abstract]
- Cell. 2026 Oct 29;189(22):6951-6967.e12.
- Cell. 2022 Sep 1;185(18):3356-3374.e22. [Abstract]
- Cell. 2021 Sep 2;184(18):4753-4771.e27. [Abstract]
- Mol Cancer. 2024 Mar 22;23(1):60. [Abstract]
- Nat Nanotechnol. 2021 Oct;16(10):1150-1160. [Abstract]
- Cell Res. 2026 Jul;36(7):513-530. [Abstract]
- Cell Res. 2023 Mar;33(3):215-228. [Abstract]
- Gastroenterology. 2021 Nov;161(5):1601-1614.e23. [Abstract]
- Mater Today. 2025 Sep 2.
- Cell Mol Immunol. 2020 May;17(5):496-506. [Abstract]
- Bioact Mater. 2024 Jun 24:40:445-459. [Abstract]
- Bioact Mater. 2024 May 11:38:384-398. [Abstract]
- Drug Resist Updat. 2023 Feb 13;68:100951. [Abstract]
- Adv Funct Mater. 04 August 2021.
- Autophagy. 2021 Dec;17(12):3976-3991. [Abstract]
- Nat Commun. 2026 Aug 22;17(1):10258.
- Nat Commun. 2026 Jun 17.
- Nat Commun. 2026 May 28.
- Nat Commun. 2025 Jul 26;16(1):6911. [Abstract]
- Nat Commun. 2025 May 23;16(1):4793. [Abstract]
- Nat Commun. 2025 Mar 14;16(1):2526. [Abstract]
- Nat Commun. 2024 Feb 6;15(1):1118. [Abstract]
- Nat Commun. 2024 Jan 5;15(1):296. [Abstract]
- ACS Nano. 2024 Jun 18;18(24):15864-15877. [Abstract]
- ACS Nano. 2024 Mar 19;18(11):8337-8349. [Abstract]
- ACS Nano. 2023 Dec 12;17(23):23535-23544. [Abstract]
- J Adv Res. 2025 Mar 17:S2090-1232(25)00186-9. [Abstract]
- Redox Biol. 2026 Sep 2:97:104376.
- Mol Cell. 2025 Jun 19;85(12):2320-2336.e9. [Abstract]
- Nucleic Acids Res. 2020 Apr 6;48(6):2912-2923. [Abstract]
- Theranostics. 2024 Jun 17;14(10):3909-3926. [Abstract]
- Theranostics. 2021 Mar 24;11(12):5650-5674. [Abstract]
- Acta Pharm Sin B. 2026 May 19.
- Acta Pharm Sin B. 2026 May;16(5):2947-2963. [Abstract]
- Acta Pharm Sin B. 2026 Feb.
- J Exp Clin Cancer Res. 2024 Jun 26;43(1):177. [Abstract]
- J Exp Clin Cancer Res. 2024 Apr 16;43(1):115. [Abstract]
- J Clin Invest. 2024 Mar 7;134(10):e172716. [Abstract]
- J Exp Clin Cancer Res. 2023 Sep 4;42(1):228. [Abstract]
- J Exp Clin Cancer Res. 2021 Apr 30;40(1):150. [Abstract]
- Adv Sci (Weinh). 2026 Sep 27:e77976.
- Adv Sci (Weinh). 2026 Aug 11:e76878. [Abstract]
- Adv Sci (Weinh). 2026 Jun 18:e20995. [Abstract]
- Adv Sci (Weinh). 2026 Feb 3:e16660. [Abstract]
- Adv Sci (Weinh). 2025 Nov 21:e12508. [Abstract]
- Adv Sci (Weinh). 2025 Oct 29:e12652. [Abstract]
- MedComm (2020). 2025 Nov 29;6(12):e70517. [Abstract]
- Adv Sci (Weinh). 2025 Aug 28:e04922. [Abstract]
- Adv Sci (Weinh). 2025 Jul;12(25):e2501934. [Abstract]
- Adv Sci (Weinh). 2025 Jun;12(23):e2500362. [Abstract]
- Adv Sci (Weinh). 2025 Feb;12(7):e2409790. [Abstract]
- Adv Sci (Weinh). 2025 Feb;12(5):e2407387. [Abstract]
- Adv Sci (Weinh). 2024 Dec;11(45):e2405441. [Abstract]
- Adv Sci (Weinh). 2023 Mar;10(9):e2206912. [Abstract]
- Cell Rep Med. 2026 May 19;7(5):102757. [Abstract]
- Cell Rep Med. 2026 Apr 21;7(4):102691. [Abstract]
- Cell Rep Med. 2025 Apr 15;6(4):102053. [Abstract]
- Cell Rep Med. 2023 Feb 21;4(2):100911. [Abstract]
- Biomaterials. 2022 Oct:289:121800. [Abstract]
- Carbohydr Polym. 2024 Dec 15:346:122645. [Abstract]
- Asian J Pharm Sci. 2026 Jun;21(3):101167. [Abstract]
- Chem Eng J. 2026 May 12;539:177266.
- J Transl Int Med. 2026 Mar 26;14(2):237-258. [Abstract]
- Chem Eng J. 2023 Oct 21, 146685.
- J Control Release. 2018 May 10:277:23-34. [Abstract]
- Cell Death Dis. 2026 Jun 19. [Abstract]
- Cell Death Dis. 2025 Mar 12;16(1):170. [Abstract]
- Cell Death Dis. 2025 Jan 18;16(1):28. [Abstract]
- Pharmacol Res. 2024 May:203:107174. [Abstract]
- Cell Death Dis. 2021 Apr 1;12(4):338. [Abstract]
- Small. 2026 Apr;22(20):e12540. [Abstract]
- Cancer Lett. 2024 Nov 1:604:217232. [Abstract]
- Int J Biol Sci. 2024 Apr 29;20(7):2748-2762. [Abstract]
- J Immunother Cancer. 2021 Jul;9(7):e001758. [Abstract]
- Cell Commun Signal. 2026 Apr 24. [Abstract]
- Cell Commun Signal. 2025 Jul 1;23(1):306. [Abstract]
- Cell Commun Signal. 2025 Jun 4;23(1):263. [Abstract]
- Cell Commun Signal. 2025 Jan 13;23(1):22. [Abstract]
- Cell Commun Signal. 2024 Jun 13;22(1):325. [Abstract]
- Phytomedicine. 2026 Jul 25:157:158316. [Abstract]
- Phytomedicine. 2024 Dec:135:156143. [Abstract]
- Phytomedicine. 2024 Dec:135:156155. [Abstract]
- Phytomedicine. 2024 Jan:123:155180. [Abstract]
- Phytomedicine. 2023 Jul 25:116:154909. [Abstract]
- Phytomedicine. 2023 Mar:111:154673. [Abstract]
- Phytomedicine. 2023 Jan:109:154550. [Abstract]
- Phytomedicine. 2022: 154560.
- Mater Today Bio. 2026 Feb 24:37:102967. [Abstract]
- Adv Healthc Mater. 2025 Aug 11:e00602. [Abstract]
- Mater Today Bio. 2025 May 10:32:101838. [Abstract]
- Clin Cancer Res. 2023 Dec 15;29(24):5227-5243. [Abstract]
- Acta Biomater. 2026 Jul:218:244-260. [Abstract]
- Cell Death Discov. 2026 Jan 9;12(1):11. [Abstract]
- Cell Death Discov. 2025 Nov 10;11(1):520. [Abstract]
- Acta Pharmacol Sin. 2025 Oct 13. [Abstract]
- Acta Biomater. 2025 Aug:202:248-261. [Abstract]
- Acta Pharmacol Sin. 2024 Oct;45(10):2061-2076. [Abstract]
- Acta Pharmacol Sin. 2022 Jul;43(7):1843-1856. [Abstract]
- NPJ Precis Oncol. 2024 Jun 5;8(1):128. [Abstract]
- NPJ Precis Oncol. 2023 Dec 8;7(1):128. [Abstract]
- Biomater Res. 2025 Apr 14:29:0177. [Abstract]
- J Transl Med. 2024 Sep 27;22(1):871. [Abstract]
- J Transl Med. 2022 Oct 2;20(1):444. [Abstract]
- Sci China Life Sci. 2025 Aug;68(8):2348-2362. [Abstract]
- Nano Res. 13, 273-281(2020).
- Dev Cell. 2021 Sep 13;56(17):2440-2454.e6. [Abstract]
- Chin Med J (Engl). 2026 Mar 5;139(5):699-709. [Abstract]
- Oncogene. 2022 Jan;41(3):427-443. [Abstract]
- Oncogene. 2021 Dec;40(49):6666-6679. [Abstract]
- Cell Chem Biol. 2026 Jan 15;33(1):74-90.e19. [Abstract]
- Cell Chem Biol. 2024 Nov 21;31(11):1926-1941.e11. [Abstract]
- Cell Chem Biol. 2020 Nov 19;27(11):1359-1370.e8. [Abstract]
- Food Res Int. 2025 Dec;222(Pt 1):117620. [Abstract]
- Mol Ther Oncol. 2024 Jun 07.
- Neural Regen Res. 2023 Dec;18(12):2727-2732. [Abstract]
- Int J Mol Med. 2021 Oct;48(4):193. [Abstract]
- EMBO J. 2022 Mar 15;41(6):e108946. [Abstract]
- Mol Med. 2025 May 6;31(1):172. [Abstract]
- Phytother Res. 2022 Aug;36(8):3313-3324. [Abstract]
- Free Radic Biol Med. 2025 Dec 16:241:367-383. [Abstract]
- EMBO Mol Med. 2025 Nov 19. [Abstract]
- Clin Transl Med. 2025 Jan;15(1):e70193. [Abstract]
- Cancer Immunol Res. 2023 May 3;11(5):583-599. [Abstract]
- ACS Appl Mater Interfaces. 2026 Mar 11;18(9):13670-13689. [Abstract]
- ACS Appl Mater Interfaces. 2026 Feb 11;18(5):7845-7862. [Abstract]
- ACS Appl Mater Interfaces. 2026 Jan 25. [Abstract]
- Stem Cell Res Ther. 2022 May 12;13(1):197. [Abstract]
- ACS Appl Mater Interfaces. 2021 Aug 4;13(30):35248-35265. [Abstract]
- Cell Rep. 2026 Mar 12;45(3):117087. [Abstract]
- Cell Rep. 2023 Nov 12;42(11):113420. [Abstract]
- Cell Rep. 2023 Jan 31;42(1):111916. [Abstract]
- Cancer Drug Resist. 2026 Aug 31:9:32.
- Cell Prolif. 2021 May;54(5):e13038. [Abstract]
- Br J Pharmacol. 2026 Jul;183(13):3666-3684. [Abstract]
- Br J Pharmacol. 2025 May 13. [Abstract]
- Br J Pharmacol. 2022 Jul;179(13):3346-3362. [Abstract]
- Cell Syst. 2019 Jul 24;9(1):35-48.e5. [Abstract]
- Int J Oncol. 2026 Jan;68(1):10. [Abstract]
- Int J Oncol. 2023 Sep;63(3):103. [Abstract]
- Anal Chem. 2023 Apr 11;95(14):6191. [Abstract]
- Int J Oncol. 2022 Dec;61(6):148. [Abstract]
- Cancer Cell Int. 2025 Oct 15;25(1):357. [Abstract]
- Cancer Cell Int. 2023 Oct 11;23(1):237. [Abstract]
- Fundam Res. 2023 Mar 17.
- Pharmaceutics. 2026 Sep 15;18(9):1159.
- Mol Cancer Ther. 2026 Mar 24. [Abstract]
- Mol Cancer Ther. 2021 Dec;20(12):2483-2494. [Abstract]
- Eur J Med Chem. 2024 Dec 5:279:116882. [Abstract]
- J Agric Food Chem. 2019 Feb 13;67(6):1656-1665. [Abstract]
- CNS Neurosci Ther. 2026 Aug;32(8):e71065.
- Ecotoxicol Environ Saf. 2025 Nov 15:307:119433. [Abstract]
- Thyroid. 2019 Jun;29(6):809-823. [Abstract]
- Biochem Pharmacol. 2026 Mar 15:249:117903. [Abstract]
- Biochem Pharmacol. 2025 Nov:241:117159. [Abstract]
- Cell Mol Life Sci. 2025 Feb 27;82(1):96. [Abstract]
- Biochem Pharmacol. 2023 Aug:214:115634. [Abstract]
- Biochem Pharmacol. 2022 Dec:206:115329. [Abstract]
- Cell Biosci. 2022 Aug 21;12(1):135. [Abstract]
- Biochem Pharmacol. 2018 Nov:157:285-293. [Abstract]
- Breast Cancer Res. 2025 Oct 27;27(1):189. [Abstract]
- Breast Cancer Res. 2025 Jul 6;27(1):124. [Abstract]
- Breast Cancer Res. 2021 Mar 4;23(1):29. [Abstract]
- J Cell Biol. 2026 Jan 5;225(1):e202503083. [Abstract]
- J Cell Biol. 2025 Dec 1;224(12):e202412005. [Abstract]
- Gastric Cancer. 2023 Nov;26(6):863-877. [Abstract]
- RSC Adv. 2023 Oct 12;13(43):29847-29861. [Abstract]
- Drug Des Devel Ther. 2021 Feb 15:15:577-588. [Abstract]
- Cells. 2026 Feb 23;15(4):383. [Abstract]
- Int J Pharm. 2024 Dec 5:666:124753. [Abstract]
- Int J Pharm. 2023 Apr 5:636:122846. [Abstract]
- J Funct Biomater. 2023 Jul 11;14(7):362. [Abstract]
- J Biomed Inform. 2023 Jun:142:104383. [Abstract]
- Gene Ther. 2023 Feb;30(1-2):88-100. [Abstract]
- Biomacromolecules. 2023 Feb 13;24(2):849-857. [Abstract]
- Cell Rep Methods. 2026 Jun 15;6(6):101339. [Abstract]
- Commun Biol. 2025 Jul 3;8(1):989. [Abstract]
- Commun Biol. 2024 Dec 3;7(1):1612. [Abstract]
- Cancer Immunol Immunother. 2024 Jul 2;73(9):177. [Abstract]
- Cell Rep Methods. 2023 Oct 23;3(10):100599. [Abstract]
- Commun Biol. 2022 Nov 26;5(1):1295. [Abstract]
- J Gastroenterol. 2026 May 14. [Abstract]
- Eur J Pharmacol. 2026 Mar 28:1019:178674. [Abstract]
- Eur J Pharmacol. 2024 Jun 15:973:176592. [Abstract]
- Mar Drugs. 2023 Apr 23;21(5):259. [Abstract]
- Pharmaceuticals (Basel). 2022 Sep 6;15(9):1111. [Abstract]
- Eur J Pharmacol. 2022 Aug 5:928:175130. [Abstract]
- Eur J Pharmacol. 2022 May 12;174982. [Abstract]
- Eur J Pharmacol. 2020 Oct 5:884:173359. [Abstract]
- Int Immunopharmacol. 2026 Oct 1:186:117091.
- Int Immunopharmacol. 2026 Jul 1:180:116665. [Abstract]
- ACS Appl Bio Mater. 2026 Jun 1;9(11):4723-4739. [Abstract]
- Int J Mol Sci. 2026 Jun 2;27(11):5039. [Abstract]
- Cell Oncol (Dordr). 2026 Jun 6. [Abstract]
- Biomolecules. 2026 Feb 9;16(2):269. [Abstract]
- Int J Mol Sci. 2025 Nov 28;26(23):11540. [Abstract]
- Int Immunopharmacol. 2025 Oct 10:163:115273. [Abstract]
- Cell Oncol (Dordr). 2024 Dec;47(6):2201-2215. [Abstract]
- Int J Mol Sci. 2023 Sep 13;24(18):14030. [Abstract]
- Cell Oncol (Dordr). 2022 Feb;45(1):41-56. [Abstract]
- Int J Mol Sci. 2020 Jan 29;21(3):876. [Abstract]
- Biol Direct. 2024 Sep 11;19(1):79. [Abstract]
- Mol Neurobiol. 2022 Aug;59(8):5056-5069. [Abstract]
- Food Hydrocoll Health. 2025 Jun.
- Front Pharmacol. 2021 Apr 15:12:621181. [Abstract]
- J Enzyme Inhib Med Chem. 2023 Dec;38(1):2230388. [Abstract]
- Front Cell Dev Biol. 2021 Sep 14:9:729965. [Abstract]
- J Drug Deliv Sci Technol. 2026 Sep 9;127:108931.
- ACS Omega. 2025 Nov 3;10(44):52202-52214. [Abstract]
- Microchem J. 2025 Oct 15;218:115702.
- ACS Omega. 2025 Oct 29;10(44):52562-52575. [Abstract]
- Bioorg Chem. 2024 Sep:150:107569. [Abstract]
- Molecules. 2022 Sep 9;27(18):5841. [Abstract]
- Molecules. 2020 Mar 5;25(5):1162. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2025 Jul 4;1871(7):167971. [Abstract]
- Sci Rep. 2026 Sep 7.
- Sci Rep. 2026 Sep 19.
- Sci Rep. 2026 Sep 25.
- Mater Today Commun. 2026 Apr 30;53:115309.
- Sci Rep. 2026 Jan 21;16(1):5921. [Abstract]
- Cancer Sci. 2025 Dec 5. [Abstract]
- Sci Rep. 2025 Jun 4;15(1):19590. [Abstract]
- Biol Proced Online. 2025 Jun 16;27(1):21. [Abstract]
- Sci Rep. 2024 Nov 29;14(1):29661. [Abstract]
- Int J Cancer. 2024 Jul 15;155(2):324-338. [Abstract]
- Transl Oncol. 2023 Oct:36:101746. [Abstract]
- J Mol Cell Cardiol. 2022 Dec:173:101-114. [Abstract]
- Transl Oncol. 2022 Dec:26:101540. [Abstract]
- Sci Rep. 2019 Oct 22;9(1):15099. [Abstract]
- Sci Rep. 2019 Sep 24;9(1):13786. [Abstract]
- Sci Rep. 2019 Aug 12;9(1):11677. [Abstract]
- Sci Rep. 2019 Apr 15;9(1):6032. [Abstract]
- Mol Pharm. 2018 Nov 5;15(11):4884-4897. [Abstract]
- Eur J Med Res. 2025 Aug 4;30(1):704. [Abstract]
- Cancers (Basel). 2023 Oct 18;15(20):5033. [Abstract]
- Exp Neurol. 2023 Mar:361:114315. [Abstract]
- Cancers (Basel). 2020 Aug 4;12(8):2169. [Abstract]
- Cell Signal. 2026 Dec:148:112822.
- Neuropharmacology. 2026 Nov 1:298:111083. [Abstract]
- Cell Signal. 2025 Mar:127:111534. [Abstract]
- Adv Ther. 2024 Jul 18.
- Oncol Rep. 2024 Jul;52(1):94. [Abstract]
- Cell Signal. 2024 Mar:115:111034. [Abstract]
- J Cell Mol Med. 2023 Aug;27(16):2385-2397. [Abstract]
- J Cell Mol Med. 2020 Jan;24(1):385-397. [Abstract]
- Nanomedicine (Lond). 2026 Aug;21(15):2177-2193.
- Mol Oncol. 2026 Sep 10.
- iScience. 2025 Apr 23;28(6):112509. [Abstract]
- iScience. 2024 Nov 28;27(12):111488. [Abstract]
- iScience. 2024 Jul 1;27(8):110434. [Abstract]
- iScience. 2024 Feb 9;27(3):109160. [Abstract]
- Brain Res Bull. 2022 Dec:191:30-39. [Abstract]
- iScience. 2022 Sep 6;25(10):105081. [Abstract]
- Biomedicines. 2021 Dec 10;9(12):1873. [Abstract]
- Bioconjug Chem. 2020 Mar 18;31(3):781-793. [Abstract]
- J Pharmacol Exp Ther. 2025 Sep 3;392(10):103692. [Abstract]
- FASEB J. 2024 May 31;38(10):e23661. [Abstract]
- FASEB J. 2019 Apr;33(4):5520-5534. [Abstract]
- BMC Cancer. 2026 Jul 13.
- BJU Int. 2025 Nov 3. [Abstract]
- BMC Cancer. 2025 Jan 7;25(1):24. [Abstract]
- Curr Issues Mol Biol. 2024 Dec 11;46(12):13951-13969. [Abstract]
- Eng Comput. 2024;40(3):1469-1499. [Abstract]
- J Biol Chem. 2022 Nov;298(11):102588. [Abstract]
- Toxins (Basel). 2026 Aug;18(8):321.
- Cancer Res Commun. 2026 Jul 1;6(7):1794-1813.
- ACS Pharmacol Transl Sci. 2025 Jul 7;8(8):2612-2629. [Abstract]
- PLoS Genet. 2026 Jun 3;22(6):e1012191. [Abstract]
- Cell Cycle. 2022 May;21(10):1058-1076. [Abstract]
- J Pharm Sci. 2019 Nov;108(11):3592-3598. [Abstract]
- J Biomed Res. 2026 Apr 25:1-18. [Abstract]
- Int J Med Sci. 2026 Jan 1;23(1):161-176. [Abstract]
- Mol Immunol. 2021 Oct:138:1-9. [Abstract]
- Breast Cancer (Dove Med Press). 2026 Jul 27:18:615413.
- Microbiologyopen. 2025 Dec;14(6):e70193. [Abstract]
- Toxicol Appl Pharmacol. 2024 Oct:491:117066. [Abstract]
- Toxicol Appl Pharmacol. 2024 Feb:483:116807. [Abstract]
- J Biochem Mol Toxicol. 2023 Aug;37(8):e23380. [Abstract]
- Exp Cell Res. 2026 Aug 1;461(1):115103. [Abstract]
- Mol Carcinog. 2024 Aug;63(8):1449-1466. [Abstract]
- Exp Cell Res. 2023 Nov 15;432(2):113793. [Abstract]
- Micromachines. 2021 Jun 10;12(6):681. [Abstract]
- Exp Cell Res. 2020 Aug 1;393(1):112054. [Abstract]
- Mol Carcinog. 2020 May;59(5):512-519. [Abstract]
- Cancer Med. 2019 May;8(5):2462-2473. [Abstract]
- Phytochemistry. 2026 Mar:243:114735. [Abstract]
- Transl Lung Cancer Res. 2025 Jun 30;14(6):2159-2179. [Abstract]
- Transl Lung Cancer Res. 2024 Oct 31;13(10):2698-2712. [Abstract]
- Invest New Drugs. 2022 Apr;40(2):274-289. [Abstract]
- Invest New Drugs. 2021 Aug;39(4):949-960. [Abstract]
- Biochem Biophys Rep. 2026 May 23:46:102636. [Abstract]
- Neuroscience. 2020 Feb 1:426:168-178. [Abstract]
- SLAS Discov. 2018 Aug;23(7):687-696. [Abstract]
- J Therm Biol. 2026 Jul:139:104503. [Abstract]
- Mol Biotechnol. 2024 Sep;66(9):2558-2568. [Abstract]
- Plasma Process Polym. 2021 Feb 12.
- Food Chem Toxicol. 2019 Apr:126:56-66. [Abstract]
- J Pain Res. 2026 Sep 26:19:635257. [Abstract]
- J Pain Res. 2026 Jun 3:19:604818. [Abstract]
- S Afr J Bot. 2026 Feb 9.
- 3 Biotech. 2025 Jan;15(1):7. [Abstract]
- BMC Pregnancy Childbirth. 2024 Oct 28;24(1):705. [Abstract]
- Tissue Cell. 2022 Aug:77:101815. [Abstract]
- Am J Cancer Res. 2019 Oct 1;9(10):2233-2248. [Abstract]
- Am J Cancer Res. 2017 Apr 1;7(4):903-912. [Abstract]
- J Gene Med. 2024 Sep;26(9):e3737. [Abstract]
- Behav Brain Res. 2024 Aug 5:471:115075. [Abstract]
- Biochim Biophys Acta Gen Subj. 2018 May;1862(5):1134-1147. [Abstract]
- Hum Cell. 2025 Jun 2;38(4):115. [Abstract]
- Hum Cell. 2023 Jul;36(4):1485-1500. [Abstract]
- Hum Cell. 2021 Jul;34(4):1244-1254. [Abstract]
- Clin Transl Oncol. 2022 Nov;24(11):2231-2240. [Abstract]
- FEBS Open Bio. 2020 Aug;10(8):1655-1667. [Abstract]
- J Nat Med. 2025 Apr 8. [Abstract]
- Cancer Manag Res. 2020 Dec 8:12:12623-12633. [Abstract]
- Thorac Cancer. 2020 Oct;11(10):2858-2866. [Abstract]
- Biochem Biophys Res Commun. 2024 Jan 8:691:149314. [Abstract]
- Biochem Biophys Res Commun. 2023 Aug 20:669:61-67. [Abstract]
- Eur J Neurosci. 2021 Aug;54(4):5341-5356. [Abstract]
- Clin Exp Pharmacol Physiol. 2020 Apr;47(4):677-686. [Abstract]
- Biochem Biophys Res Commun. 2020 Jan 15;521(3):596-602. [Abstract]
- Cancer Chemother Pharmacol. 2019 Nov;84(5):1133-1143. [Abstract]
- Biochem Biophys Res Commun. 2018 May 23;499(4):927-933. [Abstract]
- Onco Targets Ther. 2020 May 4:13:3777-3788. [Abstract]
- Onco Targets Ther. 2019 Sep 26:12:7897-7909. [Abstract]
- Int J Gen Med. 2026 Jul 10:19:612496.
- Bioorg Med Chem Lett. 2022 Jul 1;67:128731. [Abstract]
- Mol Cell Oncol. 2025 Dec 31;13(1):2604899. [Abstract]
- Oncol Lett. 2025 Oct 21;30(6):607. [Abstract]
- Oncol Lett. 2023 Feb 15;25(4):134. [Abstract]
- Anticancer Drugs. 2026 Jan 14. [Abstract]
- Curr Med Sci. 2025 Feb;45(1):104-113. [Abstract]
- Biochem Genet. 2025 Nov 22. [Abstract]
- Braz J Med Biol Res. 2024 Jul 1:57:e13357. [Abstract]
- Am J Transl Res. 2024 May 15;16(5):2132-2146. [Abstract]
- Anticancer Res. 2022 Jan;42(1):599-608. [Abstract]
- Biomed Chromatogr. 2024 Oct;38(10):e5984. [Abstract]
- J Asian Nat Prod Res. 2025 Jun 18:1-17. [Abstract]
- J Asthma. 2024 Oct;61(10):1328-1336. [Abstract]
- STAR Protoc. 2025 Jan 7;6(1):103539. [Abstract]
- Mol Biol. 2026 Sep 22.
- Gene Rep. 2026 Aug 8;45:102603.
- Eur J Inflamm. 2021 Mar 11.
- Res Sq. 2026 Sep 3.
- Biomed Pharmacother. 2026 Sep:202:119803.
- Res Sq. 2026 Aug 18.
- SSRN. 2026 Aug 29.
- University of Groningen. 2026.
- bioRxiv. 2026 Jul 7:2026.07.06.736733.
- Res Sq. 2026 Jul 20.
- University of Split. 2026.
- bioRxiv. 2026 Jun 3.
- SSRN. 2026 Jun 26.
- Res Sq. 2026 Jun 22.
- bioRxiv. 2026 Jun 23.
- medRxiv. 2026 Apr 18.
- bioRxiv. 2026 Apr 29.
- bioRxiv. 2026 Apr 1.
- University of Califomia San Francisco. 2026.
- bioRxiv. 2026 Mar 27.
- bioRxiv. 2026 Mar 15.
- Res Sq. 2026 Mar 26.
- Res Sq. 2026 Feb 26.
- bioRxiv. 2026 Feb 18:2026.02.16.706212. [Abstract]
- Res Sq. 2026 Jan 9.
- Res Sq. 2025 Dec 10.
- Patent. US20250319053A1.
- chemRxiv. 2025 Oct 22.
- bioRxiv. 2025 Sep 21.
- SSRN. 2025 Sep 26.
- Res Sq. 2025 Sep 7.
- bioRxiv. 2025 Aug 27:2025.08.22.671824. [Abstract]
- SSRN. 2025 Aug 27.
- Ursinus College. 2025.
- bioRxiv. 2025 Jul 12:2025.07.08.663754. [Abstract]
- bioRxiv. 2025 May 24.
- Complutense University of Madrid. 2025.
- bioRxiv. 2025 April 17.
- SSRN. 2025 Mar 17.
- Patent. US20240344020A1
- Res Sq. 2024 Oct 14.
- Patent. US20240344020A1.
- Biomed Pharmacother. 2024 Nov:180:117603. [Abstract]
- Biomed Pharmacother. 2024 Nov:180:117452. [Abstract]
- Res Sq. 2024 Sep 11.
- bioRxiv. 2024 August 26.
- bioRxiv. 2024 Aug 21:2024.08.20.608802. [Abstract]
- bioRxiv. 2024 June 12.
- Biomed Pharmacother. 2024 Jul:176:116871. [Abstract]
- Heliyon. 2024 May 20;10(11):e31431. [Abstract]
- SSRN. 2024 Mar 20.
- Preprints. 2024 Jan 26.
- Research Square Preprint. 2024 Jan 7.
- Universitat de València. 2023 May.
- Biomed Pharmacother. 2023 Jul:163:114751. [Abstract]
- Research Square Preprint. 2023 Jul 20.
- University of Gothenburg. 2023 Jun 27.
- bioRxiv. 2023 May 12.
- bioRxiv. 2023 Feb 28.
- Arch Cancer Res. 2023 Jan 30.
- AfricArXiv Preprints. 2212.
- Research Square Print. September 27th, 2022.
- Elife. 2022 May 3;11:e69255. [Abstract]
- Research Square Preprint. 2022 Feb.
- Biomed Pharmacother. 2021 Dec:144:112331. [Abstract]
- Research Square Preprint. 2021 Nov.
- Research Square Preprint. 2021 Jul.
- Health Sci J. (2021): 1-7.
- South Dakota State University. 2021 Apr.
- Research Square Preprint. 2021 Feb.
- Adıyaman University Journal of Science. 2020; 10(2): 427-440.
- Biomed Pharmacother. 2020 Sep:129:110356. [Abstract]
- Universitat Politècnica de València. 2020 Jul.
- bioRxiv. 2020 Jun.
- Environ Toxicol. 2020 May;35(5):561-569. [Abstract]
- Aging (Albany NY). 2020 Mar 22;12(6):5336-5351. [Abstract]
- bioRxiv. September 11, 2018.
- Universidade do Porto. 2015-11-16.
- Universidade do Porto. 2015 Sep.
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
RT-PCR
-
Cell Proliferation/Viability Assay
-
WB
Alle ADC Payloads Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
Chemical Information
-
CAS. Nr. 33069-62-4
-
Molecular Weight 853.91
-
Formel C47H51NO14
-
SMILES
O=C(N[C@H]([C@@H](O)C(O[C@@H]1C(C)=C(C(C)([C@]2(C1)O)C)[C@H](C([C@]3([C@]([H])([C@@H]2OC(C4=CC=CC=C4)=O)[C@]5(OC(C)=O)CO[C@@]5(C[C@@H]3O)[H])C)=O)OC(C)=O)=O)C6=CC=CC=C6)C7=CC=CC=C7
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (422)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]2025 Dec 15;10(1):406. PMID: 41392286 -
Signal Transduct Target Ther
Elaiophylin triggers paraptosis and preferentially kills ovarian cancer drug-resistant cells by inducing MAPK hyperactivation. [Abstract]2022 Sep 12;7(1):317. PMID: 36097006 -
Nature
2026 Oct;658(8137):1066-1076. PMID: 42717098 -
Nat Med
Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma. [Abstract]2024 Mar;30(3):749-761. PMID: 38287168
Paclitaxel solution purchased from MedChemExpress. Usage Cited in: Nat Med. 2024 Mar;30(3):749-761. [Abstract]
The relative cell viability of shCtl-, shNDUFB8-, and shCEMIP2-transfected cells was detected by XTT assay after paclitaxel (50 nM) plus gemcitabine treatment (A+G), single-agent 5-Fu (5-FU), and the FOLFIRINOX chemotherapy cocktail [FU+IRI+OXA: 5-FU+Irinotecan (SN-38) +Oxaliplatin] for 48h.
-
-
Cell
2022 Sep 1;185(18):3356-3374.e22. PMID: 36055199 -
Cell
Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. [Abstract]2021 Sep 2;184(18):4753-4771.e27. PMID: 34388391 -
Mol Cancer
LINC00115 promotes chemoresistant breast cancer stem-like cell stemness and metastasis through SETDB1/PLK3/HIF1α signaling. [Abstract]2024 Mar 22;23(1):60. PMID: 38520019 -
Nat Nanotechnol
Intrinsic bioactivity of black phosphorus nanomaterials on mitotic centrosome destabilization through suppression of PLK1 kinase. [Abstract]2021 Oct;16(10):1150-1160. PMID: 34354264 -
Cell Res
Compression-induced metabolic adaptation drives confined tumor cell migration and distant metastasis via malate-dependent microtubule reinforcement. [Abstract]2026 Jul;36(7):513-530. PMID: 42151565 -
Cell Res
Targeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondria. [Abstract]2023 Mar;33(3):215-228. PMID: 36627348 -
Gastroenterology
AGR2-Dependent Nuclear Import of RNA Polymerase II Constitutes a Specific Target of Pancreatic Ductal Adenocarcinoma in the Context of Wild-Type p53. [Abstract]2021 Nov;161(5):1601-1614.e23. PMID: 34303658
Paclitaxel solution purchased from MedChemExpress. Usage Cited in: Gastroenterology. 2021 Nov;161(5):1601-1614.e23. [Abstract]
Bar graphs show the GI50 of 5-fluoruracil (48 h), irinotecan (48 h), gemcitabine (48 h), paclitaxel (48 h), and oxaliplatin (48 h) in PDAC cells in combination with bioactive hexapeptides (NTAIYY and PTTIYY) or controls (saline and NTAIYA).
-
-
Cell Mol Immunol
2020 May;17(5):496-506. PMID: 31160756 -
Bioact Mater
Concerting magnesium implant degradation facilitates local chemotherapy in tumor-associated bone defect. [Abstract]2024 Jun 24:40:445-459. PMID: 39027327 -
Bioact Mater
Biomimetic hydrogels with mesoscale collagen architecture for patient-derived tumor organoids culture. [Abstract]2024 May 11:38:384-398. PMID: 38764448
Paclitaxel solution purchased from MedChemExpress. Usage Cited in: Bioact Mater. 2024 May 11:38:384-398. [Abstract]
Paclitaxel (10 μM; 3–5 days) reduced the activity of lung cancer organoid-3 (LCO-3) with no significant effect on the activity of LCO-1 and LCO-2.
-
Drug Resist Updat
Replacing the tropolonic methoxyl group of colchicine with methylamino increases tubulin binding affinity with improved therapeutic index and overcomes paclitaxel cross-resistance. [Abstract]2023 Feb 13;68:100951. PMID: 36841134 -
-
Autophagy
2021 Dec;17(12):3976-3991. PMID: 33752561 -
-
-
-
Nat Commun
Enhancing tandem mass spectrometry-based metabolite annotation with online chemical labeling. [Abstract]2025 Jul 26;16(1):6911. PMID: 40715063 -
Nat Commun
Oral ENPP1 inhibitor designed using generative AI as next generation STING modulator for solid tumors. [Abstract]2025 May 23;16(1):4793. PMID: 40410143 -
Nat Commun
2025 Mar 14;16(1):2526. PMID: 40087304 -
Nat Commun
Redox-responsive polymer micelles co-encapsulating immune checkpoint inhibitors and chemotherapeutic agents for glioblastoma therapy. [Abstract]2024 Feb 6;15(1):1118. PMID: 38320994 -
Nat Commun
Nuclear membrane protein SUN2 promotes replication of flaviviruses through modulating cytoskeleton reorganization mediated by NS1. [Abstract]2024 Jan 5;15(1):296. PMID: 38177122 -
ACS Nano
Celecoxib Augments Paclitaxel-Induced Immunogenic Cell Death in Triple-Negative Breast Cancer. [Abstract]2024 Jun 18;18(24):15864-15877. PMID: 38829727
Paclitaxel solution purchased from MedChemExpress. Usage Cited in: ACS Nano. 2024 Jun 18;18(24):15864-15877. [Abstract]
Paclitaxel (PTX, 0.1-1 μM; 24 h) increases COX-2 mRNA expression in 4T1 cells in a dose-dependent manner and induces elevated PGE2 release in the culture medium.
-
ACS Nano
Coassembly Nanomedicine Mediated by Intermolecular Interactions Between Methotrexate and Baricitinib for Improved Rheumatoid Arthritis Treatment. [Abstract]2024 Mar 19;18(11):8337-8349. PMID: 38437640 -
ACS Nano
A Side-Effect-Free Interventional Therapy for Precisely Eliminating Unresectable Cancer Pain. [Abstract]2023 Dec 12;17(23):23535-23544. PMID: 38084419 -
J Adv Res
Mitochondrial fatty acid oxidation as the target for blocking therapy-resistance and inhibiting tumor recurrence: The proof-of-principle model demonstrated for ovarian cancer cells. [Abstract]2025 Mar 17:S2090-1232(25)00186-9. PMID: 40107354 -
-
Mol Cell
The RNA-stability-independent role of the RNA m6A reader YTHDF2 in promoting protein translation to confer tumor chemotherapy resistance. [Abstract]2025 Jun 19;85(12):2320-2336.e9. PMID: 40480228 -
Nucleic Acids Res
HDAC8 cooperates with SMAD3/4 complex to suppress SIRT7 and promote cell survival and migration. [Abstract]2020 Apr 6;48(6):2912-2923. PMID: 31970414 -
Theranostics
Caspase-mediated AURKA cleavage at Asp132 is essential for paclitaxel to elicit cell apoptosis. [Abstract]2024 Jun 17;14(10):3909-3926. PMID: 38994036 -
Theranostics
Endogenous glutamate determines ferroptosis sensitivity via ADCY10-dependent YAP suppression in lung adenocarcinoma. [Abstract]2021 Mar 24;11(12):5650-5674. PMID: 33897873 -
-
Acta Pharm Sin B
DeepICER: A deep learning framework for predicting compound-induced gene expression profiles. [Abstract]2026 May;16(5):2947-2963. PMID: 42180546 -
-
J Exp Clin Cancer Res
Neddylation activated TRIM25 desensitizes triple-negative breast cancer to paclitaxel via TFEB-mediated autophagy. [Abstract]2024 Jun 26;43(1):177. PMID: 38926803 -
J Exp Clin Cancer Res
CCAAT enhancer binding protein delta activates vesicle associated membrane protein 3 transcription to enhance chemoresistance and extracellular PD-L1 expression in triple-negative breast cancer. [Abstract]2024 Apr 16;43(1):115. PMID: 38627816 -
J Clin Invest
DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models. [Abstract]2024 Mar 7;134(10):e172716. PMID: 38451729
Paclitaxel solution purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Mar 7;134(10):e172716. [Abstract]
The given cell lines were treated with 250 nM osimertinib (Osim), 1.25 μM Etoposide (VP-16), 125 nM Doxorubicin (DXR), 5 nM Paclitaxel, 10 μM Cisplatin, 25 μM Carboplatin, 25 nM Gemcitabine, 20 nM 5-Fluorouracil (5-FU), 25 μM Cyclophosphamide, 25 μM Capecitabine, or 10 nM Vincristine alone or in combination for 3 days. Cell numbers were then measured using the SRB assay.
-
J Exp Clin Cancer Res
Deubiquitylase YOD1 regulates CDK1 stability and drives triple-negative breast cancer tumorigenesis. [Abstract]2023 Sep 4;42(1):228. PMID: 37667382 -
J Exp Clin Cancer Res
ZBTB28 induces autophagy by regulation of FIP200 and Bcl-XL facilitating cervical cancer cell apoptosis. [Abstract]2021 Apr 30;40(1):150. PMID: 33931087 -
-
Adv Sci (Weinh)
Deciphering Anti-Cancer Drug Efficacy Through Nanomechanical Vibrations in Living Gastric Cancer Organoids. [Abstract]2026 Aug 11:e76878. PMID: 42579611 -
Adv Sci (Weinh)
FGF13 Deficiency Ameliorates Paclitaxel-Induced Neuropathic Pain by Inhibiting VASH1-Mediated Microtubule Detyrosination to Promote Mitophagy. [Abstract]2026 Jun 18:e20995. PMID: 42312425 -
Adv Sci (Weinh)
2026 Feb 3:e16660. PMID: 41632021 -
Adv Sci (Weinh)
Efferocytosis-Driven Polyamine Metabolism in Macrophages Enhances Cancer Stem Cell Enrichment after Chemotherapy in Ovarian Cancer. [Abstract]2025 Nov 21:e12508. PMID: 41271556 -
Adv Sci (Weinh)
The Crosstalk Between CRL5 and APC/C E3 Ligases Regulates Metastasis and Chemosensitivity of Cancer Cells. [Abstract]2025 Oct 29:e12652. PMID: 41159544 -
MedComm (2020)
KSQ-4279, an Inhibitor of Ubiquitin Specific Peptidase 1, Enhanced the Chemotherapeutic Efficacy in ABCB1/ABCG2/ABCC1-Mediated Multidrug Resistant Cancers. [Abstract]2025 Nov 29;6(12):e70517. PMID: 41328326 -
Adv Sci (Weinh)
Mesenchymal Stromal Cells Play an Analgesic Role Through a Npy2r Sensory Neuron-Mediated Lung-to-Brain Axis. [Abstract]2025 Aug 28:e04922. PMID: 40874463 -
Adv Sci (Weinh)
EccDNA-Driven VPS41 Amplification Alleviates Genotoxic Stress via Lysosomal KAI1 Degradation. [Abstract]2025 Jul;12(25):e2501934. PMID: 40271553 -
Adv Sci (Weinh)
Pia Mater-Penetrable Lipopolymer Nanoparticles for Gliocyte-Targeted IL-10 mRNA Therapy Alleviate Paclitaxel-Induced Peripheral Neuropathy. [Abstract]2025 Jun;12(23):e2500362. PMID: 40364590 -
Adv Sci (Weinh)
Pyruvate Kinase M2-Responsive Release of Paclitaxel and Indoleamine 2,3-Dioxygenase Inhibitor for Immuno-Chemotherapy of Nonsmall Cell Lung Cancer. [Abstract]2025 Feb;12(7):e2409790. PMID: 39716923 -
Adv Sci (Weinh)
DNMT3a Downregulation Ttriggered Upregulation of GABAA Receptor in the mPFC Promotes Paclitaxel-Induced Pain and Anxiety in Male Mice. [Abstract]2025 Feb;12(5):e2407387. PMID: 39679872 -
Adv Sci (Weinh)
The Tumor Suppressor TPD52-Governed Endoplasmic Reticulum Stress is Modulated by APCCdc20. [Abstract]2024 Dec;11(45):e2405441. PMID: 39401430 -
Adv Sci (Weinh)
Overcoming the On-Target Toxicity in Antibody-Mediated Therapies via an Indirect Active Targeting Strategy. [Abstract]2023 Mar;10(9):e2206912. PMID: 36683161 -
Cell Rep Med
Sex-biased intratumoral microbiome influences tumor molecular and immune landscape and disease outcomes. [Abstract]2026 May 19;7(5):102757. PMID: 42013847 -
Cell Rep Med
HE4 drives PD-L1 expression in myeloid cells via IFN-γR-JAK-STAT3 signaling to promote tumor immune evasion. [Abstract]2026 Apr 21;7(4):102691. PMID: 41861828 -
Cell Rep Med
CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]2025 Apr 15;6(4):102053. PMID: 40187357 -
Cell Rep Med
Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study. [Abstract]2023 Feb 21;4(2):100911. PMID: 36657446 -
Biomaterials
2022 Oct:289:121800. PMID: 36166893 -
Carbohydr Polym
Chitosan/dextran-based organohydrogel delivers EZH2 inhibitor to epigenetically reprogram chemo/immuno-resistance in unresectable metastatic melanoma. [Abstract]2024 Dec 15:346:122645. PMID: 39245506 -
Asian J Pharm Sci
Chimeric biohybrid nanovesicles induce immunogenic cell death for targeted and immune-potentiated glioblastoma therapy. [Abstract]2026 Jun;21(3):101167. PMID: 42325249 -
-
J Transl Int Med
Anti-SIA-cIgG enhances chemotherapy effectiveness through PTPN13-regulated tumor stemness in head and neck squamous cell carcinoma. [Abstract]2026 Mar 26;14(2):237-258. PMID: 42046805 -
-
J Control Release
Design and tuning of a cell-penetrating albumin derivative as a versatile nanovehicle for intracellular drug delivery. [Abstract]2018 May 10:277:23-34. PMID: 29530390 -
Cell Death Dis
Targeting the PARP10-BCAT2 axis disrupts branched-chain amino-acid metabolism to suppress bone metastasis in lung cancer. [Abstract]2026 Jun 19. PMID: 42321186 -
Cell Death Dis
Both direct and indirect suppression of MCL1 synergizes with BCLXL inhibition in preclinical models of gastric cancer. [Abstract]2025 Mar 12;16(1):170. PMID: 40075071 -
Cell Death Dis
Inhibition of KLF5 promotes ferroptosis via the ZEB1/HMOX1 axis to enhance sensitivity to oxaliplatin in cancer cells. [Abstract]2025 Jan 18;16(1):28. PMID: 39827156 -
Pharmacol Res
Depletion of regulatory T cells enhancing the anti-tumor effect of in situ vaccination in solid tumors. [Abstract]2024 May:203:107174. PMID: 38580185 -
Cell Death Dis
2021 Apr 1;12(4):338. PMID: 33795638 -
Small
Self-Assembled Carrier-Free Nanomedicines Potentiate Chemo-Photothermal Immunotherapy by Overcoming Prostaglandin E2-Mediated Immunosuppression. [Abstract]2026 Apr;22(20):e12540. PMID: 41665479 -
Cancer Lett
The deubiquitinase OTUD5 stabilizes SLC7A11 to promote progression and reduce paclitaxel sensitivity in triple-negative breast cancer. [Abstract]2024 Nov 1:604:217232. PMID: 39276913 -
Int J Biol Sci
Nuclear Softness Promotes the Metastatic Potential of Large-Nucleated Colorectal Cancer Cells via the ErbB4-Akt1-Lamin A/C Signaling Pathway. [Abstract]2024 Apr 29;20(7):2748-2762. PMID: 38725859 -
J Immunother Cancer
ATM/NEMO signaling modulates the expression of PD-L1 following docetaxel chemotherapy in prostate cancer. [Abstract]2021 Jul;9(7):e001758. PMID: 34301812 -
Cell Commun Signal
Mechanism of L-Buthionine-(S,R)-sulfoximine-induced ferroptotic cell death in mouse hippocampal neuronal cells. [Abstract]2026 Apr 24. PMID: 42032582 -
Cell Commun Signal
Phosphorylated IRF3 promotes GSDME-mediated pyroptosis through RIPK1/FADD/caspase-8 complex formation during mitotic arrest in ovarian cancer. [Abstract]2025 Jul 1;23(1):306. PMID: 40597187 -
Cell Commun Signal
2025 Jun 4;23(1):263. PMID: 40462136 -
Cell Commun Signal
Targeting the ERK1/2 and p38 MAPK pathways attenuates Golgi tethering factor golgin-97 depletion-induced cancer progression in breast cancer. [Abstract]2025 Jan 13;23(1):22. PMID: 39800687 -
Cell Commun Signal
BI-2865, a pan-KRAS inhibitor, reverses the P-glycoprotein induced multidrug resistance in vitro and in vivo. [Abstract]2024 Jun 13;22(1):325. PMID: 38872211 -
Phytomedicine
Mollugin induces ferroptosis through dysregulation of iron homeostasis and redox balance in non-small cell lung cancer. [Abstract]2026 Jul 25:157:158316. PMID: 42241811 -
Phytomedicine
Fangchinoline suppresses hepatocellular carcinoma by regulating ROS accumulation via the TRIM7/Nrf2 signaling pathway. [Abstract]2024 Dec:135:156143. PMID: 39461200 -
Phytomedicine
Artemisitene induces apoptosis of breast cancer cells by targeting FDFT1 and inhibits the growth of breast cancer patient-derived organoids. [Abstract]2024 Dec:135:156155. PMID: 39461203 -
Phytomedicine
Ginsenoside Rh2 enhances immune surveillance of natural killer (NK) cells via inhibition of ERp5 in breast cancer. [Abstract]2024 Jan:123:155180. PMID: 38043385 -
Phytomedicine
Sophflarine A, a novel matrine-derived alkaloid from Sophora flavescens with therapeutic potential for non-small cell lung cancer through ROS-mediated pyroptosis and autophagy. [Abstract]2023 Jul 25:116:154909. PMID: 37269775 -
Phytomedicine
Khellin as a selective monoamine oxidase B inhibitor ameliorated paclitaxel-induced peripheral neuropathy in mice. [Abstract]2023 Mar:111:154673. PMID: 36716674 -
Phytomedicine
Crystal structure of tubulin-barbigerone complex enables rational design of potent anticancer agents with isoflavone skeleton. [Abstract]2023 Jan:109:154550. PMID: 36610121 -
-
Mater Today Bio
Nanocomposite hydrogel acupoint therapy for sustained pregabalin delivery and long-term neuropathic pain relief. [Abstract]2026 Feb 24:37:102967. PMID: 41809379 -
Adv Healthc Mater
Novel Drug-Testing Platform for Vascular Injury-induced Intimal Hyperplasia Using a Microphysiological System. [Abstract]2025 Aug 11:e00602. PMID: 40787716 -
Mater Today Bio
Nanotube topography inhibits NLRP3 inflammasome activation by reducing microtubule glutamylation. [Abstract]2025 May 10:32:101838. PMID: 40487178 -
Clin Cancer Res
CD24hiCD27+ Bregs within Metastatic Lymph Nodes Promote Multidrug Resistance in Breast Cancer. [Abstract]2023 Dec 15;29(24):5227-5243. PMID: 37831062 -
Acta Biomater
Mechanically heterogeneous nanofibrous hydrogel drives Piezo1-mediated cell aggregation and collective migration. [Abstract]2026 Jul:218:244-260. PMID: 42270027 -
Cell Death Discov
MSLN-mediated activation of EGFR-ERK1/2 signaling drives liver metastasis in breast cancer. [Abstract]2026 Jan 9;12(1):11. PMID: 41513618 -
Cell Death Discov
NRG1/PDGFC loop between fibroblasts and cancer cells drives paclitaxel resistance via ferroptosis suppression in breast cancer. [Abstract]2025 Nov 10;11(1):520. PMID: 41213930 -
Acta Pharmacol Sin
Nobiletin and polydatin synergistically alleviate triple-negative breast cancer liver metastasis via suppressing ECM1a-mediated fatty acid biosynthesis. [Abstract]2025 Oct 13. PMID: 41083594 -
Acta Biomater
Redox-responsive dendritic copolymer-drug conjugates enhance therapeutic mitophagy through coordinated microtubule destabilization for synergistic triple-negative breast cancer therapy. [Abstract]2025 Aug:202:248-261. PMID: 40555336 -
Acta Pharmacol Sin
Desloratadine ameliorates paclitaxel-induced peripheral neuropathy and hypersensitivity reactions in mice. [Abstract]2024 Oct;45(10):2061-2076. PMID: 38789495 -
Acta Pharmacol Sin
Ras inhibitor farnesylthiosalicylic acid conjugated with IR783 dye exhibits improved tumor-targeting and altered anti-breast cancer mechanisms in mice. [Abstract]2022 Jul;43(7):1843-1856. PMID: 34845369 -
NPJ Precis Oncol
Targeting the DYRK1A kinase prevents cancer progression and metastasis and promotes cancer cells response to G1/S targeting chemotherapy drugs. [Abstract]2024 Jun 5;8(1):128. PMID: 38839871 -
NPJ Precis Oncol
Single-organoid analysis reveals clinically relevant treatment-resistant and invasive subclones in pancreatic cancer. [Abstract]2023 Dec 8;7(1):128. PMID: 38066116 -
Biomater Res
Engineered Endometrial Clear Cell Cancer-on-a-Chip Reveals Early Invasion-Metastasis Cascade of Cancer Cells. [Abstract]2025 Apr 14:29:0177. PMID: 40231208 -
J Transl Med
Vascular restenosis following paclitaxel-coated balloon therapy is attributable to NLRP3 activation and LIN9 upregulation. [Abstract]2024 Sep 27;22(1):871. PMID: 39334121 -
J Transl Med
CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial-mesenchymal transition, G2/M phase transition, and PANoptosis. [Abstract]2022 Oct 2;20(1):444. PMID: 36184616 -
Sci China Life Sci
2025 Aug;68(8):2348-2362. PMID: 40410652 -
-
Dev Cell
Gene copy-number changes and chromosomal instability induced by aneuploidy confer resistance to chemotherapy. [Abstract]2021 Sep 13;56(17):2440-2454.e6. PMID: 34352223 -
Chin Med J (Engl)
Inhibitory effect of blestriarene C on triple-negative breast cancer: Inducing ferroptosis and mitophagy via SESN2/AKT/FOXO4 axis. [Abstract]2026 Mar 5;139(5):699-709. PMID: 41527177 -
Oncogene
Disrupted mitochondrial homeostasis coupled with mitotic arrest generates antineoplastic oxidative stress. [Abstract]2022 Jan;41(3):427-443. PMID: 34773075 -
Oncogene
TTPAL promotes gastric tumorigenesis by directly targeting NNMT to activate PI3K/AKT signaling. [Abstract]2021 Dec;40(49):6666-6679. PMID: 34642500 -
Cell Chem Biol
Suppression of pain transmission and behavior by inhibition of peripheral diacylglycerol metabolism. [Abstract]2026 Jan 15;33(1):74-90.e19. PMID: 41544618 -
Cell Chem Biol
A highly potent bi-thiazole inhibitor of LOX rewires collagen architecture and enhances chemoresponse in triple-negative breast cancer. [Abstract]2024 Nov 21;31(11):1926-1941.e11. PMID: 39043186 -
Cell Chem Biol
Pharmacological Targeting of Vacuolar H+-ATPase via Subunit V1G Combats Multidrug-Resistant Cancer. [Abstract]2020 Nov 19;27(11):1359-1370.e8. PMID: 32649904 -
Food Res Int
Glycyrrhiza uralensis Fisch: A novel source of analgesic activity through NaV1.8 sodium channel modulation. [Abstract]2025 Dec;222(Pt 1):117620. PMID: 41267240 -
-
Neural Regen Res
Fidgetin interacting with microtubule end binding protein EB3 affects axonal regrowth in spinal cord injury. [Abstract]2023 Dec;18(12):2727-2732. PMID: 37449637 -
Int J Mol Med
Proteasome inhibitors decrease paclitaxel‑induced cell death in nasopharyngeal carcinoma with the accumulation of CDK1/cyclin B1. [Abstract]2021 Oct;48(4):193. PMID: 34435645 -
EMBO J
Pharmacological CDK4/6 inhibition reveals a p53-dependent senescent state with restricted toxicity. [Abstract]2022 Mar 15;41(6):e108946. PMID: 34985783 -
Mol Med
Paclitaxel alleviates spinal cord injury via activation of the Wnt/β-catenin signaling pathway. [Abstract]2025 May 6;31(1):172. PMID: 40329167 -
Phytother Res
Higher efficacy of resveratrol against advanced breast cancer organoids: A comparison with that of clinically relevant drugs. [Abstract]2022 Aug;36(8):3313-3324. PMID: 35649509 -
Free Radic Biol Med
Cavidine alleviates paclitaxel-induced peripheral neuropathy by promoting mitochondrial autophagy through inhibiting PKM2-mediated histone lactylation. [Abstract]2025 Dec 16:241:367-383. PMID: 41005738 -
EMBO Mol Med
Activated glucocorticoid receptor is an estrogen receptor silencer in ER+ metastatic breast cancer. [Abstract]2025 Nov 19. PMID: 41261233 -
Clin Transl Med
Pathogenic variants of TUBB8 cause oocyte spindle defects by disrupting with EB1/CAKP5 interactions and potential treatment targeting microtubule acetylation through HDAC6 inhibition. [Abstract]2025 Jan;15(1):e70193. PMID: 39834092 -
Cancer Immunol Res
Discovery of podofilox as a potent cGAMP-STING signaling enhancer with antitumor activity. [Abstract]2023 May 3;11(5):583-599. PMID: 36921097 -
ACS Appl Mater Interfaces
Calcium-Overloaded Multifunctional Nanoparticles for Synergistically Enhanced Photothermal and Chemotherapy and Immune Activation in Triple-Negative Breast Cancer. [Abstract]2026 Mar 11;18(9):13670-13689. PMID: 41769838 -
ACS Appl Mater Interfaces
Hypoxia Alleviation-Potentiated Chemotherapy Enhances Anti-PD-L1 Treatment for Triple-Negative Breast Cancer via Improving Tumor Immunogenicity and Inhibiting STAT3 Activation. [Abstract]2026 Feb 11;18(5):7845-7862. PMID: 41618887 -
ACS Appl Mater Interfaces
2026 Jan 25. PMID: 41582522 -
Stem Cell Res Ther
Epiregulin increases stemness-associated genes expression and promotes chemoresistance of non-small cell lung cancer via ERK signaling. [Abstract]2022 May 12;13(1):197. PMID: 35551652 -
ACS Appl Mater Interfaces
Peptide-Targeted High-Density Lipoprotein Nanoparticles for Combinatorial Treatment against Metastatic Breast Cancer. [Abstract]2021 Aug 4;13(30):35248-35265. PMID: 34284582 -
Cell Rep
Targeting the DSTYK-ULK1 axis rewires TNFR1 signaling to overcome treatment resistance in lung cancer. [Abstract]2026 Mar 12;45(3):117087. PMID: 41824459 -
Cell Rep
Incorporation of human iPSC-derived stromal cells creates a pancreatic cancer organoid with heterogeneous cancer-associated fibroblasts. [Abstract]2023 Nov 12;42(11):113420. PMID: 37955987 -
Cell Rep
The deubiquitinase OTUD1 noncanonically suppresses Akt activation through its N-terminal intrinsically disordered region. [Abstract]2023 Jan 31;42(1):111916. PMID: 36640312 -
-
Cell Prolif
2021 May;54(5):e13038. PMID: 33793020 -
Br J Pharmacol
Cimigenoside enhances Taxol chemosensitivity in triple-negative breast cancer via the γ-secretase/RBPJ-PXR axis. [Abstract]2026 Jul;183(13):3666-3684. PMID: 41933509 -
Br J Pharmacol
Contributions of synaptic energetic dysfunction by microtubule dynamics and microtubule-based mitochondrial transport disorder to morphine tolerance. [Abstract]2025 May 13. PMID: 40361281 -
Br J Pharmacol
Targeted disruption of mitochondria potently reverses multidrug resistance in cancer therapy. [Abstract]2022 Jul;179(13):3346-3362. PMID: 35040123 -
Cell Syst
A Multi-center Study on the Reproducibility of Drug-Response Assays in Mammalian Cell Lines. [Abstract]2019 Jul 24;9(1):35-48.e5. PMID: 31302153 -
Int J Oncol
Discovery of the late autophagy inhibitor FZU‑0045‑053 and its anti‑breast cancer and immunomodulatory effects. [Abstract]2026 Jan;68(1):10. PMID: 41312734 -
Int J Oncol
Ipatasertib exhibits anti‑tumorigenic effects and enhances sensitivity to paclitaxel in endometrial cancer in vitro and in vivo. [Abstract]2023 Sep;63(3):103. PMID: 37503790 -
Anal Chem
Label-Free Isolation of Low-Adhesion Cells with Stem Properties for Cancer Stem Cell-Specific Drug Evaluation. [Abstract]2023 Apr 11;95(14):6191. PMID: 36122350 -
Int J Oncol
A novel ferroptosis‑related gene signature for overall survival prediction and immune infiltration in patients with breast cancer. [Abstract]2022 Dec;61(6):148. PMID: 36222299 -
Cancer Cell Int
Establishment and characteristic analysis of a novel patient derived cell line of intrahepatic cholangiocarcinoma. [Abstract]2025 Oct 15;25(1):357. PMID: 41094661 -
Cancer Cell Int
A novel STAT3/ NFκB p50 axis regulates stromal-KDM2A to promote M2 macrophage-mediated chemoresistance in breast cancer. [Abstract]2023 Oct 11;23(1):237. PMID: 37821959 -
-
-
Mol Cancer Ther
DHX9 inhibition enhances paclitaxel sensitivity by inducing mitotic failure in ovarian and endometrial cancers. [Abstract]2026 Mar 24. PMID: 41873535 -
Mol Cancer Ther
Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199. [Abstract]2021 Dec;20(12):2483-2494. PMID: 34711645 -
Eur J Med Chem
Design, synthesis and biological evaluation of plant-derived miliusol derivatives achieve TNBC profound regression in vivo. [Abstract]2024 Dec 5:279:116882. PMID: 39305634 -
J Agric Food Chem
Discovery of Myricetin as a Potent Inhibitor of Human Flap Endonuclease 1, Which Potentially Can Be Used as Sensitizing Agent against HT-29 Human Colon Cancer Cells. [Abstract]2019 Feb 13;67(6):1656-1665. PMID: 30694659
Paclitaxel solution purchased from MedChemExpress. Usage Cited in: J Agric Food Chem. 2019 Feb 13;67(6):1656-1665. [Abstract]
Western blot image and statistical analysis of phosphorylated γH2AX levels in HT-29 cells with different treatments after 48 h. Myricetin and PTX used are 32 μM and 100 nM, respectively.
-
-
Ecotoxicol Environ Saf
PPARγ-responsive luciferase reporter system for high-throughput screening of chemical toxins with potential pulmonary fibrosis effects. [Abstract]2025 Nov 15:307:119433. PMID: 41273832 -
Thyroid
Targeting Super-Enhancer-Driven Oncogenic Transcription by CDK7 Inhibition in Anaplastic Thyroid Carcinoma. [Abstract]2019 Jun;29(6):809-823. PMID: 30924726 -
Biochem Pharmacol
Ticagrelor reverses multidrug resistance in breast cancer by inhibiting PI3K/AKT/mTOR pathway and suppressing ABCB1 expression and function. [Abstract]2026 Mar 15:249:117903. PMID: 41846011 -
Biochem Pharmacol
Discovery of a potent BRD4 PROTAC and evaluation of its bioactivity in breast cancer cell lines. [Abstract]2025 Nov:241:117159. PMID: 40659131 -
Cell Mol Life Sci
Glycocalyx hyaluronan removal-induced increasing of cell stiffness delays breast cancer cells progression. [Abstract]2025 Feb 27;82(1):96. PMID: 40011237 -
Biochem Pharmacol
VPS34-IN1 induces apoptosis of ER + breast cancer cells via activating PERK/ATF4/CHOP pathway. [Abstract]2023 Aug:214:115634. PMID: 37290596 -
Biochem Pharmacol
A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in p53-positive breast cancer. [Abstract]2022 Dec:206:115329. PMID: 36309080 -
Cell Biosci
Anti-tumor effects of dual PI3K-HDAC inhibitor CUDC-907 on activation of ROS-IRE1α-JNK-mediated cytotoxic autophagy in esophageal cancer. [Abstract]2022 Aug 21;12(1):135. PMID: 35989326 -
Biochem Pharmacol
Appraising the "entourage effect": Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer. [Abstract]2018 Nov:157:285-293. PMID: 29940172 -
Breast Cancer Res
Multi-receptor targeted therapy of breast cancer and brain metastases with a novel QUAD-drug conjugate. [Abstract]2025 Oct 27;27(1):189. PMID: 41146202 -
Breast Cancer Res
THEM6 modulates carboplatin sensitivity by regulating ferroptosis through FDFT1 in triple-negative breast cancer. [Abstract]2025 Jul 6;27(1):124. PMID: 40619388 -
Breast Cancer Res
First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models. [Abstract]2021 Mar 4;23(1):29. PMID: 33663585 -
J Cell Biol
2026 Jan 5;225(1):e202503083. PMID: 41236476 -
J Cell Biol
Adapting plasma membrane for mitotic cell rounding through Aurora A phosphorylation of numb. [Abstract]2025 Dec 1;224(12):e202412005. PMID: 41212116 -
Gastric Cancer
Anthracycline chemicals with anthracyclinone structure exert antitumor effects by inhibiting angiogenesis and lymphangiogenesis in a xenografted gastric tumor model. [Abstract]2023 Nov;26(6):863-877. PMID: 37344705 -
RSC Adv
A novel label-free electrochemical immunosensor for the detection of heat shock protein 70 of lung adenocarcinoma cell line following paclitaxel treatment using l-cysteine-functionalized Au@MnO2/MoO3 nanocomposites. [Abstract]2023 Oct 12;13(43):29847-29861. PMID: 37842680 -
Drug Des Devel Ther
Effects of Quercetin on the Efficacy of Various Chemotherapeutic Drugs in Cervical Cancer Cells. [Abstract]2021 Feb 15:15:577-588. PMID: 33623367 -
Cells
A Comprehensive Adenoid Cystic Carcinoma-Derived Organoid Platform for Disease Modeling and Drug Screening Captures Interpatient Heterogeneity. [Abstract]2026 Feb 23;15(4):383. PMID: 41744826 -
Int J Pharm
Mesenchymal stem cell-delivered paclitaxel nanoparticles exhibit enhanced efficacy against a syngeneic orthotopic mouse model of pancreatic cancer. [Abstract]2024 Dec 5:666:124753. PMID: 39321899 -
Int J Pharm
Surface-modified nanoparticles of docetaxel for chemotherapy of lung cancer: an intravenous to oral switch. [Abstract]2023 Apr 5:636:122846. PMID: 36921744 -
J Funct Biomater
A Potential Effect of Circadian Rhythm in the Delivery/Therapeutic Performance of Paclitaxel-Dendrimer Nanosystems. [Abstract]2023 Jul 11;14(7):362. PMID: 37504857 -
J Biomed Inform
2023 Jun:142:104383. PMID: 37196989 -
Gene Ther
Exosomal PD-L1 confers chemoresistance and promotes tumorigenic properties in esophageal cancer cells via upregulating STAT3/miR-21. [Abstract]2023 Feb;30(1-2):88-100. PMID: 35440807 -
Biomacromolecules
2023 Feb 13;24(2):849-857. PMID: 36639133 -
Cell Rep Methods
Tumor immune microenvironment reconstitution in patient-derived organoids enables therapy modeling for NSCLC. [Abstract]2026 Jun 15;6(6):101339. PMID: 42134319 -
Commun Biol
2025 Jul 3;8(1):989. PMID: 40610677 -
Commun Biol
Development and validation of the Normalized Organoid Growth Rate (NOGR) metric in brightfield imaging-based assays. [Abstract]2024 Dec 3;7(1):1612. PMID: 39627437 -
Cancer Immunol Immunother
GSDME-mediated pyroptosis promotes anti-tumor immunity of neoadjuvant chemotherapy in breast cancer. [Abstract]2024 Jul 2;73(9):177. PMID: 38954046 -
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618 -
Commun Biol
A pipeline for malignancy and therapy agnostic assessment of cancer drug response using cell mass measurements. [Abstract]2022 Nov 26;5(1):1295. PMID: 36435843 -
J Gastroenterol
Chemotherapy-induced cell cycle arrest is associated with increased claudin-18 isoform 2 expression and enhanced zolbetuximab-mediated cytotoxicity in gastric cancer. [Abstract]2026 May 14. PMID: 42133042 -
Eur J Pharmacol
DNMT3A-regulated medial prefrontal cortex circuits modulate paclitaxel-induced neuropathic pain. [Abstract]2026 Mar 28:1019:178674. PMID: 41740780 -
Eur J Pharmacol
IP3R1 dysregulation via mir-200c-3p/SSFA2 axis contributes to taxol resistance in head and neck cancer. [Abstract]2024 Jun 15:973:176592. PMID: 38642666 -
Mar Drugs
Marine Sulfated Polysaccharide PMGS Synergizes with Paclitaxel in Inhibiting Cervical Cancer In Vitro. [Abstract]2023 Apr 23;21(5):259. PMID: 37233453
Paclitaxel solution purchased from MedChemExpress. Usage Cited in: Mar Drugs. 2023 Apr 23;21(5):259. [Abstract]
Paclitaxel (PTX; 3.125, 6.25, 12.5, 25, 50, 100 nM; 48 h) reduces the viability of Hela, SiHa, and C33A cells in a dose-dependent manner.(3.125 nM for Hela cells, 100 nM for SiHa and C33A cells)
Paclitaxel solution purchased from MedChemExpress. Usage Cited in: Mar Drugs. 2023 Apr 23;21(5):259. [Abstract]
Paclitaxel (PTX; 50 nM; 48 h) increases the expression of Cleaved-caspase-9 and Cleaved-caspase-3 in Hela cells.
-
Pharmaceuticals (Basel)
2022 Sep 6;15(9):1111. PMID: 36145332 -
Eur J Pharmacol
Notch signaling activation contributes to paclitaxel-induced neuropathic pain via activation of A1 astrocytes. [Abstract]2022 Aug 5:928:175130. PMID: 35777441 -
Eur J Pharmacol
Screening of and mechanism underlying the action of serum- and glucocorticoid-regulated kinase 3-targeted drugs against estrogen receptor-positive breast cancer. [Abstract]2022 May 12;174982. PMID: 35569550 -
Eur J Pharmacol
MiR-375 inhibits the stemness of breast cancer cells by blocking the JAK2/STAT3 signaling. [Abstract]2020 Oct 5:884:173359. PMID: 32738343 -
-
Int Immunopharmacol
Targeting NBL1/PI3K/AKT axis to enhance the chemosensitivity and radiosensitivity of esophageal squamous cell carcinoma. [Abstract]2026 Jul 1:180:116665. PMID: 42030890 -
ACS Appl Bio Mater
Amphiphilic Glycopolymer Nanoparticles for pH-Responsive Paclitaxel Delivery and Enhanced Efficacy in Pancreatic Ductal Adenocarcinoma Therapy. [Abstract]2026 Jun 1;9(11):4723-4739. PMID: 42138136 -
Int J Mol Sci
ABCG2 Contributes to Multidrug Resistance and Aggressive Phenotypes Associated with ERK Signaling in Gastric Cancer. [Abstract]2026 Jun 2;27(11):5039. PMID: 42278563 -
Cell Oncol (Dordr)
P2RY6+ tumor-associated macrophages as a therapeutic target: suppressing tumor growth and enhancing chemosensitivity in triple-negative breast cancer. [Abstract]2026 Jun 6. PMID: 42250059 -
Biomolecules
Mesenchymal Stem Cell Exosome-Mediated Delivery of Paclitaxel for Pancreatic Cancer Therapy. [Abstract]2026 Feb 9;16(2):269. PMID: 41750339 -
Int J Mol Sci
2025 Nov 28;26(23):11540. PMID: 41373692 -
Int Immunopharmacol
2025 Oct 10:163:115273. PMID: 40743622 -
Cell Oncol (Dordr)
Inhibition of EREG/ErbB/ERK by Astragaloside IV reversed taxol-resistance of non-small cell lung cancer through attenuation of stemness via TGFβ and Hedgehog signal pathway. [Abstract]2024 Dec;47(6):2201-2215. PMID: 39373858 -
Int J Mol Sci
CRISPR/Cas9-Mediated CtBP1 Gene Editing Enhances Chemosensitivity and Inhibits Metastatic Potential in Esophageal Squamous Cell Carcinoma Cells. [Abstract]2023 Sep 13;24(18):14030. PMID: 37762332 -
Cell Oncol (Dordr)
AZD4547 targets the FGFR/Akt/SOX2 axis to overcome paclitaxel resistance in head and neck cancer. [Abstract]2022 Feb;45(1):41-56. PMID: 34837170 -
Int J Mol Sci
(+)-Usnic Acid Induces ROS-dependent Apoptosis via Inhibition of Mitochondria Respiratory Chain Complexes and Nrf2 Expression in Lung Squamous Cell Carcinoma. [Abstract]2020 Jan 29;21(3):876. PMID: 32013250 -
Biol Direct
Integrative genomics unveils basement membrane-related diagnostic markers and therapeutic targets in esophageal squamous cell carcinoma. [Abstract]2024 Sep 11;19(1):79. PMID: 39256753 -
Mol Neurobiol
Functional Investigation of TUBB4A Variants Associated with Different Clinical Phenotypes. [Abstract]2022 Aug;59(8):5056-5069. PMID: 35668344 -
-
Front Pharmacol
Guaiazulene Triggers ROS-Induced Apoptosis and Protective Autophagy in Non-small Cell Lung Cancer. [Abstract]2021 Apr 15:12:621181. PMID: 33935713 -
J Enzyme Inhib Med Chem
PD-L1 dimerisation induced by biphenyl derivatives mediates anti-breast cancer activity via the non-immune PD-L1-AKT-mTOR/Bcl2 pathway. [Abstract]2023 Dec;38(1):2230388. PMID: 37439326 -
Front Cell Dev Biol
HIF1α Regulates IL17 Signaling Pathway Influencing Sensitivity of Taxane-Based Chemotherapy for Breast Cancer. [Abstract]2021 Sep 14:9:729965. PMID: 34595177 -
-
ACS Omega
Piceatannol and Pumpkin Seed Oil Synergistically Promote Apoptosis of PC3 Prostate Cancer Cells via Intrinsic Mitochondrial Pathway. [Abstract]2025 Nov 3;10(44):52202-52214. PMID: 41244467 -
-
ACS Omega
Association Study of OATP1B3 Polymorphisms on Hepatic Uptake and Drug-Drug Interaction In Vitro. [Abstract]2025 Oct 29;10(44):52562-52575. PMID: 41244417 -
Bioorg Chem
The cytotoxic natural compound erianin binds to colchicine site of β-tubulin and overcomes taxane resistance. [Abstract]2024 Sep:150:107569. PMID: 38905886 -
Molecules
A Carabrane-Type Sesquiterpenolide Carabrone from Carpesium cernuum Inhibits SW1990 Pancreatic Cancer Cells by Inducing Ferroptosis. [Abstract]2022 Sep 9;27(18):5841. PMID: 36144577 -
Molecules
Design, Synthesis, and Biological Evaluation of Aromatic Amide-Substituted Benzimidazole-Derived Chalcones. The Effect of Upregulating TP53 Protein Expression. [Abstract]2020 Mar 5;25(5):1162. PMID: 32150865 -
Biochim Biophys Acta Mol Basis Dis
Anticancer and chemo-sensitizing effects of annonacin via p53-mediated DNA damage in ovarian cancer. [Abstract]2025 Jul 4;1871(7):167971. PMID: 40618909 -
-
-
-
-
Sci Rep
Deploying the high-throughput virtual screening (HTVS) approach for the identification of new lactate dehydrogenase (LDH) inhibitors with anticancer assets. [Abstract]2026 Jan 21;16(1):5921. PMID: 41565942 -
Cancer Sci
MASTL Promotes Hepatocellular Carcinoma Progression and Paclitaxel Resistance Through Mitotic Catastrophe. [Abstract]2025 Dec 5. PMID: 41347427 -
Sci Rep
The hydroxamate based HDAC inhibitor WMJ-J-09 induces colorectal cancer cell death by targeting tubulin and downregulating survivin. [Abstract]2025 Jun 4;15(1):19590. PMID: 40467895 -
Biol Proced Online
Establishment of a mouse lung cancer organoid model and its applications for therapeutic screening. [Abstract]2025 Jun 16;27(1):21. PMID: 40524168 -
Sci Rep
Biological and genetic characterization of a newly established human primary multidrug-resistant distal cholangiocarcinoma cell line, CBC3T-6. [Abstract]2024 Nov 29;14(1):29661. PMID: 39613883 -
Int J Cancer
Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients. [Abstract]2024 Jul 15;155(2):324-338. PMID: 38533706 -
Transl Oncol
CircSLC39A8 attenuates paclitaxel resistance in ovarian cancer by regulating the miR‑185‑5p/BMF axis. [Abstract]2023 Oct:36:101746. PMID: 37499410 -
J Mol Cell Cardiol
Defective autophagy triggered by arterial cyclic stretch promotes neointimal hyperplasia in vein grafts via the p62/nrf2/slc7a11 signaling pathway. [Abstract]2022 Dec:173:101-114. PMID: 36308866 -
Transl Oncol
2022 Dec:26:101540. PMID: 36115073 -
Sci Rep
Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination. [Abstract]2019 Oct 22;9(1):15099. PMID: 31641154 -
Sci Rep
2019 Sep 24;9(1):13786. PMID: 31551480 -
Sci Rep
Matrix Metalloproteinase Expressions Play Important role in Prediction of Ovarian Cancer Outcome. [Abstract]2019 Aug 12;9(1):11677. PMID: 31406154 -
Sci Rep
Unveiling novel targets of paclitaxel resistance by single molecule long-read RNA sequencing in breast cancer. [Abstract]2019 Apr 15;9(1):6032. PMID: 30988345 -
Mol Pharm
Synthesis and Characterization of PDMS-PMOXA-Based Polymersomes Sensitive to MMP-9 for Application in Breast Cancer. [Abstract]2018 Nov 5;15(11):4884-4897. PMID: 30274515 -
Eur J Med Res
Long non-coding RNA NORAD serves as a promoter of oncogenesis and inhibits ferroptosis via miR-144-3p-mTOR-ferritinophagy axis in cancer. [Abstract]2025 Aug 4;30(1):704. PMID: 40760677 -
Cancers (Basel)
USP53 Exerts Tumor-Promoting Effects in Triple-Negative Breast Cancer by Deubiquitinating CRKL. [Abstract]2023 Oct 18;15(20):5033. PMID: 37894400 -
Exp Neurol
2023 Mar:361:114315. PMID: 36586551 -
Cancers (Basel)
Identification of Cardiac Glycosides as Novel Inhibitors of eIF4A1-Mediated Translation in Triple-Negative Breast Cancer Cells. [Abstract]2020 Aug 4;12(8):2169. PMID: 32759815 -
-
Neuropharmacology
DNMT3a-mediated GluN2B desilencing in the anterior cingulate cortex underlies chemotherapy-induced neuropathic pain. [Abstract]2026 Nov 1:298:111083. PMID: 42341912 -
Cell Signal
Inhibition of XIST restrains paclitaxel resistance in breast cancer cells by targeting hsa-let-7d-5p/ATG16L1 through regulation of autophagy. [Abstract]2025 Mar:127:111534. PMID: 39638138 -
-
Oncol Rep
Ursolic acid inhibits the proliferation of triple‑negative breast cancer stem‑like cells through NRF2‑mediated ferroptosis. [Abstract]2024 Jul;52(1):94. PMID: 38847277 -
Cell Signal
An integrative pan-cancer analysis of WWC family genes and functional validation in lung cancer. [Abstract]2024 Mar:115:111034. PMID: 38190957 -
J Cell Mol Med
Integrated analysis identifies RAC3 as an immune-related prognostic biomarker associated with chemotherapy sensitivity in endometrial cancer. [Abstract]2023 Aug;27(16):2385-2397. PMID: 37386813 -
J Cell Mol Med
Toll-like receptor 4 regulates spontaneous intestinal tumorigenesis by up-regulating IL-6 and GM-CSF. [Abstract]2020 Jan;24(1):385-397. PMID: 31650683 -
-
-
iScience
Utidelone suppresses PDAC growth and enhances gemcitabine therapy by inducing immunogenic cell death. [Abstract]2025 Apr 23;28(6):112509. PMID: 40530421 -
iScience
Amitriptyline revitalizes ICB response via dually inhibiting Kyn/Indole and 5-HT pathways of tryptophan metabolism in ovarian cancer. [Abstract]2024 Nov 28;27(12):111488. PMID: 39759009 -
iScience
2024 Jul 1;27(8):110434. PMID: 39108714 -
iScience
PBRM1 presents a potential ctDNA marker to monitor response to neoadjuvant chemotherapy in cervical cancer. [Abstract]2024 Feb 9;27(3):109160. PMID: 38414861 -
Brain Res Bull
Lysine-specific Demethylase 1 in Primary Sensory Neurons Participates in Chronic Compression of Dorsal Root Ganglion-induced Neuropathic Pain. [Abstract]2022 Dec:191:30-39. PMID: 36240908 -
iScience
Multiomic characterization and drug testing establish circulating tumor cells as an ex vivo tool for personalized medicine. [Abstract]2022 Sep 6;25(10):105081. PMID: 36204272 -
Biomedicines
An Orthotopic Model of Uveal Melanoma in Zebrafish Embryo: A Novel Platform for Drug Evaluation. [Abstract]2021 Dec 10;9(12):1873. PMID: 34944689 -
Bioconjug Chem
Design, Synthesis, and Characterization of a Paclitaxel Formulation Activated by Extracellular MMP9. [Abstract]2020 Mar 18;31(3):781-793. PMID: 31894970 -
J Pharmacol Exp Ther
Morusin reverses paclitaxel resistance by inhibiting the stem cell-like properties of non-small cell lung cancer in a β-catenin-dependent manner. [Abstract]2025 Sep 3;392(10):103692. PMID: 40997566 -
FASEB J
FGF13 enhances the function of TRPV1 by stabilizing microtubules and regulates acute and chronic itch. [Abstract]2024 May 31;38(10):e23661. PMID: 38733310 -
FASEB J
2019 Apr;33(4):5520-5534. PMID: 30668917 -
-
BJU Int
Drug-releasing intravesical floating technology for sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer. [Abstract]2025 Nov 3. PMID: 41178321 -
BMC Cancer
Preclinical studies of the falnidamol as a highly potent and specific active ABCB1 transporter inhibitor. [Abstract]2025 Jan 7;25(1):24. PMID: 39773145 -
Curr Issues Mol Biol
Transcriptomic Profiling of Carboplatin- and Paclitaxel-Resistant Lung Adenocarcinoma Cells Reveals CSF3 as a Potential Biomarker for the Carboplatin Plus Paclitaxel Doublet Regimens. [Abstract]2024 Dec 11;46(12):13951-13969. PMID: 39727962 -
Eng Comput
A global sensitivity analysis of a mechanistic model of neoadjuvant chemotherapy for triple negative breast cancer constrained by in vitro and in vivo imaging data. [Abstract]2024;40(3):1469-1499. PMID: 39620056 -
J Biol Chem
Cell adhesion molecule CD44v10 promotes stem-like properties in triple-negative breast cancer cells via glucose transporter GLUT1-mediated glycolysis. [Abstract]2022 Nov;298(11):102588. PMID: 36243113 -
-
-
ACS Pharmacol Transl Sci
Antineuroblastoma Activity Evaluation and Mechanism of Novel PD-L1 Small Molecule Inhibitors through Immune and Non-Immune Pathways. [Abstract]2025 Jul 7;8(8):2612-2629. PMID: 40810160 -
PLoS Genet
Barrier-to-autointegration factor protects against the cGAS-STING response to chromatin bridges. [Abstract]2026 Jun 3;22(6):e1012191. PMID: 42234713 -
Cell Cycle
Ultrasound-targeted microbubble destruction-mediated miR-144-5p overexpression enhances the anti-tumor effect of paclitaxel on thyroid carcinoma by targeting STON2. [Abstract]2022 May;21(10):1058-1076. PMID: 35184686 -
J Pharm Sci
α1-Acid Glycoprotein Has the Potential to Serve as a Biomimetic Drug Delivery Carrier for Anticancer Agents. [Abstract]2019 Nov;108(11):3592-3598. PMID: 31288036 -
J Biomed Res
Hypoxia-induced acidic microenvironment alters cellular pharmacokinetics of gastric cancer in a Mongolian population. [Abstract]2026 Apr 25:1-18. PMID: 41953981 -
Int J Med Sci
Integrative analysis identifies PIGK as an oncogenic glycosylphosphatidylinositol transamidase subunit with prognostic, immunological, and therapeutic relevance in head and neck cancer. [Abstract]2026 Jan 1;23(1):161-176. PMID: 41399371 -
Mol Immunol
LINC00337 induces tumor development and chemoresistance to paclitaxel of breast cancer by recruiting M2 tumor-associated macrophages. [Abstract]2021 Oct:138:1-9. PMID: 34314939 -
-
Microbiologyopen
Fungal Colonization by Malassezia globosa Promotes Breast Cancer Progression and M2 Macrophage Polarization Through the MBL-C3a-C3aR Signaling Pathway. [Abstract]2025 Dec;14(6):e70193. PMID: 41381403 -
Toxicol Appl Pharmacol
Nicotinamide riboside activates SIRT3 to prevent paclitaxel-induced peripheral neuropathy. [Abstract]2024 Oct:491:117066. PMID: 39128506
Paclitaxel solution purchased from MedChemExpress. Usage Cited in: Toxicol Appl Pharmacol. 2024 Oct:491:117066. [Abstract]
WB images of SIRT3, AcK68-MnSOD and AcK122-MnSOD expressions in DRG tissues. Quantification of SIRT3, AcK68-MnSOD and AcK122-MnSOD expressions normalized with β-actin expressions and the Saline+Saline treated samples was set to 1 (NR (Nicotinamide riboside chloride); PTX (4 mg/kg, i. p.) Group, PTX (4 mg/kg, i.p.) + NR (400 mg/kg, i.g.) Group, PTX (4 mg/kg, I.P.) + NR (400 mg/kg, i.g.) +3-TYP (50 mg/kg, i.p.) group, NR (400 mg/kg, i.p.) group, 3-TYP (50 mg/kg, i.p.) group in SIRT3 WT mice)
Paclitaxel solution purchased from MedChemExpress. Usage Cited in: Toxicol Appl Pharmacol. 2024 Oct:491:117066. [Abstract]
The representative images depicting the expression of AcK68-MnSOD in each group were utilized for immunohistochemical detection (NR (Nicotinamide riboside chloride); PTX (4 mg/kg, i. p.) Group, PTX (4 mg/kg, i.p.) + NR (400 mg/kg, i.g.) Group, PTX (4 mg/kg, I.P.) + NR (400 mg/kg, i.g.) +3-TYP (50 mg/kg, i.p.) group, NR(400 mg/kg, i.p.) group, 3-TYP (50 mg/kg, i.p.) group in SIRT3 WT mice)
-
Toxicol Appl Pharmacol
2024 Feb:483:116807. PMID: 38199493 -
J Biochem Mol Toxicol
MIAT shuttled by tumor-secreted exosomes promotes paclitaxel resistance in esophageal cancer cells by activating the TAF1/SREBF1 axis. [Abstract]2023 Aug;37(8):e23380. PMID: 37132394 -
Exp Cell Res
2026 Aug 1;461(1):115103. PMID: 42276196 -
Mol Carcinog
Curcuminoid PBPD induces cuproptosis and endoplasmic reticulum stress in cervical cancer via the Notch1/RBP-J/NRF2/FDX1 pathway. [Abstract]2024 Aug;63(8):1449-1466. PMID: 38801356 -
Exp Cell Res
Angelicin inhibits cell growth and promotes apoptosis in oral squamous cell carcinoma by negatively regulating DUSP6/cMYC signaling pathway. [Abstract]2023 Nov 15;432(2):113793. PMID: 37741490 -
Micromachines
2021 Jun 10;12(6):681. PMID: 34200752 -
Exp Cell Res
Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]2020 Aug 1;393(1):112054. PMID: 32376287 -
Mol Carcinog
2020 May;59(5):512-519. PMID: 32124501 -
Cancer Med
Zinc cooperates with p53 to inhibit the activity of mitochondrial aconitase through reactive oxygen species accumulation. [Abstract]2019 May;8(5):2462-2473. PMID: 30972978 -
Phytochemistry
Phytochemical study of Fissistigma fulgens (Hook.f. & Thomson) Merr. leaves: Previously undescribed dihydrochalcone derivatives and their biological activities. [Abstract]2026 Mar:243:114735. PMID: 41344390 -
Transl Lung Cancer Res
Development of a 3D-3 co-culture microbead consisting of cancer-associated fibroblasts and human umbilical vein endothelial cells for the anti-tumor drug assessment of lung cancer. [Abstract]2025 Jun 30;14(6):2159-2179. PMID: 40673102 -
Transl Lung Cancer Res
Construction of a lung cancer 3D culture model based on alginate/gelatin micro-beads for drug evaluation. [Abstract]2024 Oct 31;13(10):2698-2712. PMID: 39507032 -
Invest New Drugs
Ad-VT enhances the sensitivity of chemotherapy-resistant lung adenocarcinoma cells to gemcitabine and paclitaxel in vitro and in vivo. [Abstract]2022 Apr;40(2):274-289. PMID: 34981275 -
Invest New Drugs
Autophagy promotes oncolysis of an adenovirus expressing apoptin in human bladder cancer models. [Abstract]2021 Aug;39(4):949-960. PMID: 33534026 -
Biochem Biophys Rep
Exploration of the multi-component, multi-target, and multi-pathway mechanism of Rubia yunnanensis in inhibiting breast cancer based on network pharmacology, molecular docking, and experimental validation. [Abstract]2026 May 23:46:102636. PMID: 42232767 -
Neuroscience
Paclitaxel Induces Sex-biased Behavioral Deficits and Changes in Gene Expression in Mouse Prefrontal Cortex. [Abstract]2020 Feb 1:426:168-178. PMID: 31846751 -
SLAS Discov
A Multiplexed Screening Assay to Evaluate Chemotherapy-Induced Myelosuppression Using Healthy Peripheral Blood and Bone Marrow. [Abstract]2018 Aug;23(7):687-696. PMID: 29865911 -
J Therm Biol
Sequential cryoablation enhances chemotherapeutic efficacy in pancreatic cancer by downregulating TGF-β mediated fibrosis in the sub-lethal zone. [Abstract]2026 Jul:139:104503. PMID: 42284933 -
Mol Biotechnol
Verteporfin Exerts Anticancer Effects and Reverses Resistance to Paclitaxel via Inducing Ferroptosis in Esophageal Squamous Cell Cancer Cells. [Abstract]2024 Sep;66(9):2558-2568. PMID: 37751128 -
-
Food Chem Toxicol
Scandenolone from Cudrania tricuspidata fruit extract suppresses the viability of breast cancer cells (MCF-7) in vitro and in vivo. [Abstract]2019 Apr:126:56-66. PMID: 30753858 -
J Pain Res
Electroacupuncture Ameliorates Hyperalgesia and Anxiety-Like Behaviors in Chemotherapy-Induced Peripheral Neuropathy Mice Through Inhibition of Astrocyte-Mediated Neuronal Activation in the Anterior Cingulate Cortex. [Abstract]2026 Sep 26:19:635257. PMID: 42820061 -
J Pain Res
Wrist-Ankle Acupuncture Alleviates Paclitaxel-Induced Neuropathic Pain in Mice by Neuronal α7 Nicotinic Acetylcholine Receptor-Dependent Modulation of Spinal Glutamatergic/NMDAR Signaling. [Abstract]2026 Jun 3:19:604818. PMID: 42267150 -
-
3 Biotech
POU4F1 enhances lung cancer gemcitabine resistance by regulating METTL3-dependent TWF1 mRNA N6 adenosine methylation. [Abstract]2025 Jan;15(1):7. PMID: 39676891 -
BMC Pregnancy Childbirth
2024 Oct 28;24(1):705. PMID: 39468487 -
Tissue Cell
Vitamin D enhances the sensitivity of breast cancer cells to the combination therapy of photodynamic therapy and paclitaxel. [Abstract]2022 Aug:77:101815. PMID: 35623307 -
Am J Cancer Res
The resistance of esophageal cancer cells to paclitaxel can be reduced by the knockdown of long noncoding RNA DDX11-AS1 through TAF1/TOP2A inhibition. [Abstract]2019 Oct 1;9(10):2233-2248. PMID: 31720085 -
Am J Cancer Res
2017 Apr 1;7(4):903-912. PMID: 28469962
Paclitaxel solution purchased from MedChemExpress. Usage Cited in: Am J Cancer Res. 2017 Apr 1;7(4):903-912. [Abstract]
Synergistic inhibition of colony formation of ATC cells by E7080 and Paclitaxel. Representative images of colony formation in C643 cells treated with vehicle control (DMSO) or E7080 and Paclitaxel at the indicated concentrations, individually or in combination, are shown in left panel. Quantitative analysis of colony numbers is shown in right panel.
-
J Gene Med
Oncogenic tRNA-derived fragment tRF-Leu-CAG promotes tumorigenesis of lung cancer via targeting TCEA3 and increasing autophagy. [Abstract]2024 Sep;26(9):e3737. PMID: 39198937 -
Behav Brain Res
Astroglial morphological changes in periaqueductal grey in different pain and itch mice models. [Abstract]2024 Aug 5:471:115075. PMID: 38815698 -
Biochim Biophys Acta Gen Subj
2018 May;1862(5):1134-1147. PMID: 29410075
Paclitaxel solution purchased from MedChemExpress. Usage Cited in: Biochim Biophys Acta Gen Subj. 2018 May;1862(5):1134-1147. [Abstract]
The effects of CS1 on polymerized microtubules are also investigated using a cellular tubulin polymer assay. Nocodazole (1 μM) and Paclitaxel (1.5 μM) are used as depolymerization and polymerization controls, respectively.
-
Hum Cell
Establishment and comparison of three sublines from a human uterine carcinosarcoma cell line, ESCA. [Abstract]2025 Jun 2;38(4):115. PMID: 40455147 -
Hum Cell
TIPE2 sensitizes breast cancer cells to paclitaxel by suppressing drug-induced autophagy and cancer stem cell properties. [Abstract]2023 Jul;36(4):1485-1500. PMID: 36964413 -
Hum Cell
Long non-coding RNA TPT1-AS1 sensitizes breast cancer cell to paclitaxel and inhibits cell proliferation by miR-3156-5p/caspase 2 axis. [Abstract]2021 Jul;34(4):1244-1254. PMID: 33999360 -
Clin Transl Oncol
Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism. [Abstract]2022 Nov;24(11):2231-2240. PMID: 35852680 -
FEBS Open Bio
2020 Aug;10(8):1655-1667. PMID: 32594651 -
J Nat Med
Tenacissoside G reverses paclitaxel resistance by inhibiting Src/PTN/P-gp signaling axis activation in ovarian cancer cells. [Abstract]2025 Apr 8. PMID: 40195205 -
Cancer Manag Res
miR-613 Suppresses Chemoresistance and Stemness in Triple-Negative Breast Cancer by Targeting FAM83A. [Abstract]2020 Dec 8:12:12623-12633. PMID: 33324107 -
Thorac Cancer
Potential monoamine oxidase A inhibitor suppressing paclitaxel-resistant non-small cell lung cancer metastasis and growth. [Abstract]2020 Oct;11(10):2858-2866. PMID: 32875729 -
Biochem Biophys Res Commun
Pemigatinib, a selective FGFR inhibitor overcomes ABCB1-mediated multidrug resistance in cancer cells. [Abstract]2024 Jan 8:691:149314. PMID: 38039831 -
Biochem Biophys Res Commun
Cloning, expression of porcine GSDME and identification of its site cleaved by caspase-3. [Abstract]2023 Aug 20:669:61-67. PMID: 37267861
Paclitaxel solution purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2023 Aug 20:669:61-67. [Abstract]
Paclitaxel (25, 50 μM; 24 h) significantly increases the expression of caspase-3 in PK-15 cells.
-
Eur J Neurosci
Ketogenic diet prevents paclitaxel-induced neuropathic nociception through activation of PPARγ signalling pathway and inhibition of neuroinflammation in rat dorsal root ganglion. [Abstract]2021 Aug;54(4):5341-5356. PMID: 34318540 -
Clin Exp Pharmacol Physiol
Cathelicidin deficiency exacerbates cardiac dysfunction in lipopolysaccharide-induced endotoxaemic mice. [Abstract]2020 Apr;47(4):677-686. PMID: 31868940 -
Biochem Biophys Res Commun
2020 Jan 15;521(3):596-602. PMID: 31679697 -
Cancer Chemother Pharmacol
Downregulation of SRSF3 by antisense oligonucleotides sensitizes oral squamous cell carcinoma and breast cancer cells to paclitaxel treatment. [Abstract]2019 Nov;84(5):1133-1143. PMID: 31515668 -
Biochem Biophys Res Commun
PMN inhibits colorectal cancer cells through inducing mitotic arrest and p53-dependent apoptosis via the inhibition of tubulin polymerization. [Abstract]2018 May 23;499(4):927-933. PMID: 29626471 -
Onco Targets Ther
2020 May 4:13:3777-3788. PMID: 32440146 -
Onco Targets Ther
Expression Of BMP7 In Ovarian Cancer And Biological Effect Of BMP7 Knockdown On Ovarian Cancer Cells. [Abstract]2019 Sep 26:12:7897-7909. PMID: 31576147 -
-
Bioorg Med Chem Lett
New synthetic phenylquinazoline derivatives induce apoptosis by targeting the pro-survival members of the BCL-2 family. [Abstract]2022 Jul 1;67:128731. PMID: 35421577 -
Mol Cell Oncol
SNX1 inhibits human ovarian cancer progression via regulation of the cell cycle, apoptosis and migration. [Abstract]2025 Dec 31;13(1):2604899. PMID: 41487280 -
Oncol Lett
SBEM confers paclitaxel resistance in breast cancer via DUSP16-mediated MAPK/AMPK pathway activation. [Abstract]2025 Oct 21;30(6):607. PMID: 41181635 -
Oncol Lett
LPCAT1 is transcriptionally regulated by FOXA1 to promote breast cancer progression and paclitaxel resistance. [Abstract]2023 Feb 15;25(4):134. PMID: 36909375
Paclitaxel solution purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2023 Feb 15;25(4):134. [Abstract]
Paclitaxel (PTX; 0‑100 nM; 72 h) inhibits the viability of MDA‑MB‑231cells.
-
Anticancer Drugs
APG-1252 enhances the anticancer role of paclitaxel in non-small-cell lung cancer cells by suppressing the extracellular regulated protein kinases/myeloid cell leukemia 1 pathway. [Abstract]2026 Jan 14. PMID: 41608859 -
Curr Med Sci
Salidroside Enhances the Sensitivity of Lung Cancer Cells to Paclitaxel by Regulating the Wnt/β-catenin Signaling Pathway. [Abstract]2025 Feb;45(1):104-113. PMID: 40014194 -
Biochem Genet
2025 Nov 22. PMID: 41273664 -
Braz J Med Biol Res
FRAX486, a PAK inhibitor, overcomes ABCB1-mediated multidrug resistance in breast cancer cells. [Abstract]2024 Jul 1:57:e13357. PMID: 38958364 -
Am J Transl Res
RACGAP1 knockdown synergizes and enhances the effects of chemotherapeutics on ovarian cancer. [Abstract]2024 May 15;16(5):2132-2146. PMID: 38883382 -
Anticancer Res
Establishment of Patient-derived Preclinical Models for Invasive Papillary Cholangiocarcinoma. [Abstract]2022 Jan;42(1):599-608. PMID: 34969769 -
Biomed Chromatogr
P-glycoprotein-mediated herb-drug interaction evaluation between Tenacissoside G and paclitaxel. [Abstract]2024 Oct;38(10):e5984. PMID: 39152775 -
J Asian Nat Prod Res
Design, synthesis, and biological evaluation of bergapten derivatives as potent anti-pancreatic cancer agents. [Abstract]2025 Jun 18:1-17. PMID: 40531172 -
J Asthma
Paclitaxel Inhibits Proliferation by Negatively Regulating Cdk1-Cell Cycle Axis in Rat Airway Smooth Muscle Cells. [Abstract]2024 Oct;61(10):1328-1336. PMID: 38696283 -
STAR Protoc
Protocol for generating a pancreatic cancer organoid associated with heterogeneous tumor microenvironment. [Abstract]2025 Jan 7;6(1):103539. PMID: 39772386 -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
bioRxiv
Radiation synergizes with BET inhibition to stimulate durable, systemic anti-tumor immunity in murine cancer models. [Abstract]2026 Feb 18:2026.02.16.706212. PMID: 41757027 -
-
-
-
-
-
-
-
bioRxiv
2025 Aug 27:2025.08.22.671824. PMID: 40909578 -
-
-
bioRxiv
2025 Jul 12:2025.07.08.663754. PMID: 40672312 -
-
-
-
-
-
-
-
Biomed Pharmacother
Gilteritinib reverses ABCB1-mediated multidrug resistance: Preclinical in vitro and animal investigations. [Abstract]2024 Nov:180:117603. PMID: 39471652 -
Biomed Pharmacother
Paclitaxel-resistance facilitates glycolytic metabolism via Hexokinase-2-regulated ABC and SLC transporter genes in ovarian clear cell carcinoma. [Abstract]2024 Nov:180:117452. PMID: 39341074 -
-
-
bioRxiv
RBN-2397, a PARP7 Inhibitor, Synergizes with Paclitaxel to Inhibit Proliferation and Migration of Ovarian Cancer Cells. [Abstract]2024 Aug 21:2024.08.20.608802. PMID: 39229139 -
-
Biomed Pharmacother
Liensinine diperchlorate and artemisitene synergistically attenuate breast cancer progression through suppressing PI3K-AKT signaling and their efficiency in breast cancer patient-derived organoids. [Abstract]2024 Jul:176:116871. PMID: 38861856 -
Heliyon
HMGA2 promotes resistance against paclitaxel by targeting the p53 signaling pathway in colorectal cancer cells. [Abstract]2024 May 20;10(11):e31431. PMID: 38845972 -
-
-
-
-
Biomed Pharmacother
Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing. [Abstract]2023 Jul:163:114751. PMID: 37105073 -
-
-
-
-
Paclitaxel solution purchased from MedChemExpress. Usage Cited in: Arch Cancer Res. 2023 Jan 30.
Paclitaxel (CPT; 10-6 -12-10 M; 72 h) demonstrates a strong antitumor activity and an inhibitory of proliferation (IC50 = 6.28 nM) in U937 cells.
-
-
-
Elife
2022 May 3;11:e69255. PMID: 35503721 -
-
Biomed Pharmacother
β2-adrenoreceptor agonist ameliorates mechanical allodynia in paclitaxel-induced neuropathic pain via induction of mitochondrial biogenesis. [Abstract]2021 Dec:144:112331. PMID: 34673421 -
-
-
-
-
-
-
Biomed Pharmacother
PPARγ activation mitigates mechanical allodynia in paclitaxel-induced neuropathic pain via induction of Nrf2/HO-1 signaling pathway. [Abstract]2020 Sep:129:110356. PMID: 32535388 -
-
-
Environ Toxicol
The miRNA-149-5p/MyD88 axis is responsible for ursolic acid-mediated attenuation of the stemness and chemoresistance of non-small cell lung cancer cells. [Abstract]2020 May;35(5):561-569. PMID: 31855318 -
Aging (Albany NY)
Overexpressed ITGA2 contributes to paclitaxel resistance by ovarian cancer cells through the activation of the AKT/FoxO1 pathway. [Abstract]2020 Mar 22;12(6):5336-5351. PMID: 32202508 -
-
-
Reinheit & Dokumentation
Verweise
[1]. Choi YH, et al. Paclitaxel-induced growth arrest and apoptosis is associated with the upregulation of the Cdk inhibitor, p21WAF1/CIP1, in human breast cancer cells. Oncol Rep. 2012 Dec;28(6):2163-9. [Content Brief]
[2]. Dziadyk JM, et al. Paclitaxel-induced apoptosis may occur without a prior G2/M-phase arrest. Anticancer Res. 2004 Jan-Feb;24(1):27-36. [Content Brief]
[3]. Li Q, et al. Low doses of paclitaxel enhance liver metastasis of breast cancer cells in the mouse model. FEBS J. 2016 Aug;283(15):2836-52. [Content Brief]
[4]. Pan Z, et al. Paclitaxel attenuates Bcl-2 resistance to apoptosis in breast cancer cells through an endoplasmic reticulum-mediated calciumrelease in a dosage dependent manner. Biochem Biophys Res Commun. 2013 Feb 13. pii: S0006-291X(13)00259-3. [Content Brief]
[5]. Cadamuro M, et al. Low dose paclitaxel reduces S100A4 nuclear import to inhibit invasion and hematogenous metastasis of cholangiocarcinoma. Cancer Res. 2016 Jun 21. [Content Brief]
[6]. Li Q, et al. Low doses of paclitaxel enhance liver metastasis of breast cancer cells in the mouse model. FEBS J. 2016 Jun 16. [Content Brief]
[7]. Yilmaz E, et al. Sensory neuron subpopulation-specific dysregulation of intracellular calcium in a rat model of chemotherapy-induced peripheral neuropathy. Neuroscience. 2015 Aug 6;300:210-8. [Content Brief]
[8]. Jing C, et al. E7080 enhances the antitumor effects of paclitaxel in anaplastic thyroid cancer. Am J Cancer Res. 2017 Apr 1;7(4):903-912. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)